Accumulation	O
of	O
RXR	B-protein
alpha	I-protein
during	O
activation	O
of	O
cycling	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
modulation	O
of	O
RXRE	O
transactivation	O
function	O
by	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
resting	O
human	B-cell_type
immature	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
(	I-cell_type
PBT	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
is	O
associated	O
with	O
the	O
loss	O
of	O
retinoid	B-protein
X	I-protein
receptor	I-protein
alpha	I-protein
(	O
RXRalpha	B-protein
)	O
expression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
unlike	O
resting	O
cells	O
,	O
activation	O
of	O
cycling	B-cell_type
human	I-cell_type
mature	I-cell_type
PBT	I-cell_type
lymphocytes	I-cell_type
,	O
and	O
T	B-cell_line
lymphocyte	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
accompanied	O
by	O
the	O
accumulation	O
of	O
RXRalpha	B-protein
mRNA	O
and	O
protein	O
.	O

Interestingly	O
,	O
cyclosporin	O
A	O
further	O
augmented	O
RXRalpha	B-protein
expression	O
,	O
indicating	O
the	O
involvement	O
of	O
calcineurin	O
pathways	O
in	O
the	O
process	O
.	O

9-cis	O
retinoic	O
acid	O
inhibited	O
the	O
accumulation	O
,	O
suggesting	O
that	O
retinoids	O
can	O
regulate	O
the	O
synthesis	O
of	O
their	O
own	O
receptors	O
during	O
T	O
cell	O
activation	O
.	O

Transfection	O
analysis	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
using	O
RXRE-dependent	O
reporter	O
assays	O
,	O
showed	O
that	O
RXRalpha	B-protein
accumulated	O
during	O
T	O
cell	O
activation	O
was	O
transcriptionally	O
inactive	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
such	O
inhibition	O
,	O
the	O
role	O
of	O
two	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
,	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	O
modulating	O
RXRE-dependent	O
transcription	O
,	O
was	O
explored	O
.	O

The	O
expression	O
of	O
constitutively	O
active	O
MAP/ERK	B-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEKK1	B-protein
)	O
inhibited	O
RXRE-dependent	O
transcription	O
,	O
whereas	O
dominant	B-protein
negative	I-protein
MEKK1	I-protein
increased	O
the	O
transcription	O
,	O
indicating	O
the	O
involvement	O
of	O
JNK	B-protein
signaling	O
pathways	O
in	O
the	O
process	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
constitutively	B-protein
active	I-protein
MEK1	I-protein
,	O
which	O
activates	O
ERK	B-protein
pathway	O
,	O
enhanced	O
RXRE-dependent	O
activation	O
.	O

When	O
both	O
were	O
activated	O
simultaneously	O
,	O
JNK	B-protein
pathway	O
was	O
dominant	O
over	O
ERK	B-protein
pathway	O
and	O
resulted	O
in	O
inhibition	O
of	O
RXRE-mediated	O
transcription	O
.	O

These	O
data	O
demonstrate	O
a	O
dual	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
activation	O
of	O
resting	B-cell_type
and	I-cell_type
cycling	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
indicate	O
a	O
dynamic	O
balance	O
between	O
JNK	O
and	O
ERK	O
pathways	O
in	O
modulating	O
RXRE-mediated	O
transactivation	O
.	O

3	NULL
<	NULL
.	NULL

a	NULL
el	NULL
(	NULL
ap	NULL
)	NULL
D	NULL
3	NULL
Reporter	NULL
Cell	NULL
Lines	NULL
a	NULL
a	NULL
g	NULL
The	NULL
film	NULL
”	NULL
)	NULL
!	NULL

keeps	NULL
growing	NULL
Learn	NULL
more	NULL
Afx	NULL
meJournal	NULL
o	NULL
Accumulation	NULL
of	NULL
RXRo	NULL
During	NULL
Activation	NULL
of	NULL
Cycling	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
:	NULL
Modulation	NULL
ImmunOIOgy	NULL
of	NULL
RXRE	NULL
Transactivation	NULL
Function	NULL
by	NULL
Mitogen-Activated	NULL
Protein	NULL
Kinase	NULL
Pathways	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Mohammad	NULL
Ishaq	NULL
,	NULL
Ming	NULL
Fan	NULL
and	NULL
Ven	NULL
Natarajan	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
165:4217-4225	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.165.8.4217	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/8/4217	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
53	NULL
articles	NULL
,	NULL
26	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/8/4217	NULL
full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Accumulation	NULL
of	NULL
RXRa	NULL
During	NULL
Activation	NULL
of	NULL
Cycling	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
:	NULL
Modulation	NULL
of	NULL
RXRE	NULL
Transactivation	NULL
Function	NULL
by	NULL
Mitogen-Activated	NULL
Protein	NULL
Kinase	NULL
Pathways	NULL
!	NULL

Mohammad	NULL
Ishaq	NULL
,	NULL
``	NULL
Ming	NULL
Fan	NULL
,	NULL
and	NULL
Ven	NULL
Natarajan	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
human	NULL
immature	NULL
peripheral	NULL
blood	NULL
T	NULL
(	NULL
PBT	NULL
)	NULL
lymphocytes	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
retinoid	NULL
X	NULL
receptor	NULL
a	NULL
(	NULL
RXRa	NULL
)	NULL
expression	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
,	NULL
unlike	NULL
resting	NULL
cells	NULL
,	NULL
activation	NULL
of	NULL
cycling	NULL
human	NULL
mature	NULL
PBT	NULL
lymphocytes	NULL
,	NULL
and	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
cell	NULL
lines	NULL
is	NULL
accompanied	NULL
by	NULL
the	NULL
accumulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
.	NULL

Interestingly	NULL
,	NULL
cyclosporin	NULL
A	NULL
further	NULL
augmented	NULL
RXRa	NULL
expression	NULL
,	NULL
indicating	NULL
the	NULL
involvement	NULL
of	NULL
calcineurin	NULL
pathways	NULL
in	NULL
the	NULL
process	NULL
.	NULL

9-cis	NULL
retinoic	NULL
acid	NULL
inhibited	NULL
the	NULL
accumulation	NULL
,	NULL
suggesting	NULL
that	NULL
retinoids	NULL
can	NULL
regulate	NULL
the	NULL
synthesis	NULL
of	NULL
their	NULL
own	NULL
receptors	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Transfection	NULL
analysis	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
using	NULL
RXRE-dependent	NULL
reporter	NULL
assays	NULL
,	NULL
showed	NULL
that	NULL
RXRa	NULL
accumulated	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
was	NULL
transcriptionally	NULL
inactive	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
mechanism	NULL
of	NULL
such	NULL
inhibition	NULL
,	NULL
the	NULL
role	NULL
of	NULL
two	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathways	NULL
,	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
and	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
,	NULL
in	NULL
modulating	NULL
RXRE-dependent	NULL
transcription	NULL
,	NULL
was	NULL
explored	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
constitutively	NULL
active	NULL
MAP/ERK	NULL
kinase	NULL
kinase	NULL
1	NULL
(	NULL
MEKK1	NULL
)	NULL
inhibited	NULL
RXRE-dependent	NULL
transcription	NULL
,	NULL
whereas	NULL
dominant	NULL
negative	NULL
MEKK1	NULL
increased	NULL
the	NULL
transcription	NULL
,	NULL
indicating	NULL
the	NULL
involvement	NULL
of	NULL
JNK	NULL
signaling	NULL
pathways	NULL
in	NULL
the	NULL
process	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
expression	NULL
of	NULL
constitutively	NULL
active	NULL
MEK1	NULL
,	NULL
which	NULL
activates	NULL
ERK	NULL
pathway	NULL
,	NULL
enhanced	NULL
RXRE-dependent	NULL
activation	NULL
.	NULL

When	NULL
both	NULL
were	NULL
activated	NULL
simultaneously	NULL
,	NULL
JNK	NULL
pathway	NULL
was	NULL
dominant	NULL
over	NULL
ERK	NULL
pathway	NULL
and	NULL
resulted	NULL
in	NULL
inhibition	NULL
of	NULL
RXRE-mediated	NULL
transcription	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
a	NULL
dual	NULL
regulatory	NULL
control	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
and	NULL
cycling	NULL
T	NULL
lymphocytes	NULL
and	NULL
indicate	NULL
a	NULL
dynamic	NULL
balance	NULL
between	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
in	NULL
modulating	NULL
RXRE-mediated	NULL
transactivation	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2000	NULL
,	NULL
165	NULL
;	NULL
4217-4225.	NULL
ation	NULL
,	NULL
retinoids	NULL
also	NULL
influence	NULL
growth	NULL
,	NULL
development	NULL
,	NULL
and	NULL
ap-	NULL
optosis	NULL
.	NULL

These	NULL
effects	NULL
are	NULL
mediated	NULL
through	NULL
retinoid	NULL
X	NULL
receptors	NULL
(	NULL
RXRa	NULL
,	NULL
RXR	NULL
,	NULL
RXRy	NULL
)	NULL
``	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARa	NULL
,	NULL
RAR	NULL
,	NULL
RARy	NULL
)	NULL
,	NULL
a	NULL
group	NULL
of	NULL
nuclear	NULL
receptors	NULL
involved	NULL
in	NULL
retinoic	NULL
acid-mediated	NULL
gene	NULL
activation	NULL
(	NULL
1-6	NULL
)	NULL
.	NULL

These	NULL
receptors	NULL
exert	NULL
their	NULL
action	NULL
as	NULL
transcriptional	NULL
regulators	NULL
by	NULL
binding	NULL
,	NULL
as	NULL
homodimers	NULL
or	NULL
heterodimers	NULL
,	NULL
to	NULL
specific	NULL
hormone	NULL
response	NULL
elements	NULL
,	NULL
RXRE	NULL
and	NULL
RARE	NULL
,	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
target	NULL
genes	NULL
.	NULL

The	NULL
role	NULL
of	NULL
retinoid	NULL
receptors	NULL
in	NULL
the	NULL
physiology	NULL
of	NULL
T	NULL
lymphocytes	NULL
is	NULL
not	NULL
well	NULL
understood	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
various	NULL
retinoids	NULL
can	NULL
either	NULL
induce	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
or	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
T	NULL
cell	NULL
hybridomas	NULL
,	NULL
or	NULL
thy	NULL
I	NULL
n	NULL
addition	NULL
to	NULL
the	NULL
well-established	NULL
role	NULL
in	NULL
cellular	NULL
differenti-	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Cell	NULL
Biology	NULL
,	NULL
Science	NULL
Applications	NULL
International	NULL
Corpora-tion-Frederick	NULL
,	NULL
National	NULL
Cancer	NULL
Institute-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702	NULL
Received	NULL
for	NULL
publication	NULL
February	NULL
28	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
July	NULL
20	NULL
,	NULL
2000	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
project	NULL
has	NULL
been	NULL
funded	NULL
with	NULL
Federal	NULL
funds	NULL
from	NULL
the	NULL
U.S.	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
under	NULL
contract	NULL
number	NULL
NO1-CO-56000	NULL
.	NULL

The	NULL
content	NULL
of	NULL
this	NULL
publication	NULL
does	NULL
not	NULL
necessarily	NULL
reflect	NULL
the	NULL
views	NULL
or	NULL
policies	NULL
of	NULL
the	NULL
U.S.	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
,	NULL
nor	NULL
does	NULL
mention	NULL
of	NULL
trade	NULL
names	NULL
,	NULL
commercial	NULL
prod-ucts	NULL
,	NULL
or	NULL
organization	NULL
imply	NULL
endorsement	NULL
by	NULL
the	NULL
U.	NULL
S.	NULL
government	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Mohammad	NULL
Ishaq	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Cell	NULL
Biology	NULL
,	NULL
Building	NULL
550	NULL
,	NULL
Room	NULL
104	NULL
,	NULL
Science	NULL
Applications	NULL
International	NULL
Corp.-Frederick	NULL
,	NULL
National	NULL
Cancer	NULL
Institute-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702-1201	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
mishaq	NULL
@	NULL
nih.gov	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
MAP	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
;	NULL
AICD	NULL
,	NULL
activation-induced	NULL
cell	NULL
death	NULL
;	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
;	NULL
JNK	NULL
,	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
;	NULL
MEK	NULL
,	NULL
MAP/ERK	NULL
kinase	NULL
;	NULL
MEKK	NULL
,	NULL
MAP/ERK	NULL
kinase	NULL
kinase	NULL
;	NULL
ION	NULL
,	NULL
ionomycin	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
Act	NULL
D	NULL
,	NULL
actinomycin	NULL
D	NULL
;	NULL
9-CRA	NULL
,	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
;	NULL
CRBPIL	NULL
,	NULL
cellular	NULL
retinol	NULL
binding	NULL
protein	NULL
type	NULL
II	NULL
;	NULL
PBT	NULL
,	NULL
peripheral	NULL
blood	NULL
T	NULL
cell	NULL
;	NULL
CN	NULL
,	NULL
calcineurin	NULL
;	NULL
COUP-TF	NULL
,	NULL
chicken	NULL
OVA	NULL
upstream	NULL
promoter	NULL
transcription	NULL
factor	NULL
.	NULL

Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
mocytes	NULL
and	NULL
that	NULL
RXRs	NULL
and	NULL
RARs	NULL
may	NULL
have	NULL
a	NULL
role	NULL
in	NULL
modulating	NULL
the	NULL
process	NULL
(	NULL
9-14	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
triggers	NULL
multiple	NULL
signaling	NULL
pathways	NULL
including	NULL
the	NULL
activation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinases	NULL
(	NULL
15-18	NULL
)	NULL
.	NULL

These	NULL
include	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
,	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
/stress-activated	NULL
protein	NULL
kinase	NULL
(	NULL
SAPK	NULL
)	NULL
,	NULL
and	NULL
p38	NULL
.	NULL

ERK	NULL
is	NULL
activated	NULL
by	NULL
upstream	NULL
kinase	NULL
MAP/ERK	NULL
kinase	NULL
(	NULL
MEK	NULL
)	NULL
,	NULL
whereas	NULL
JNK	NULL
and	NULL
p38	NULL
are	NULL
activated	NULL
by	NULL
JNK	NULL
kinase	NULL
(	NULL
JNKK/SEK/MKK4	NULL
)	NULL
.	NULL

MEK	NULL
and	NULL
MKK4	NULL
are	NULL
activated	NULL
by	NULL
Raf-1	NULL
and	NULL
MEK	NULL
kinase	NULL
(	NULL
MEKK	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
19-22	NULL
)	NULL
.	NULL

MEKK1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
JNK	NULL
and	NULL
preferentially	NULL
activate	NULL
JNK	NULL
pathway	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
MAP	NULL
kinase	NULL
pathways	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
retinoid	NULL
receptor	NULL
signaling	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Two	NULL
different	NULL
signaling	NULL
events	NULL
occur	NULL
during	NULL
the	NULL
in	NULL
vitro	NULL
stimulation	NULL
of	NULL
resting	NULL
immature	NULL
and	NULL
actively	NULL
cycling	NULL
mature	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
both	NULL
types	NULL
of	NULL
cells	NULL
produce	NULL
IL-2	NULL
following	NULL
activation	NULL
,	NULL
only	NULL
the	NULL
resting	NULL
immature	NULL
T	NULL
cells	NULL
undergo	NULL
cell	NULL
division	NULL
and	NULL
proliferate	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
activation	NULL
of	NULL
cycling	NULL
mature	NULL
T	NULL
cells	NULL
by	NULL
Abs	NULL
to	NULL
TCR	NULL
or	NULL
PMA	NULL
plus	NULL
PHA	NULL
or	NULL
ionomycin	NULL
(	NULL
ION	NULL
)	NULL
is	NULL
known	NULL
to	NULL
suppress	NULL
their	NULL
growth	NULL
and	NULL
lead	NULL
to	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
AICD	NULL
;	NULL
Refs	NULL
.	NULL

25-28	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
RXRa	NULL
levels	NULL
in	NULL
resting	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
(	NULL
PBT	NULL
)	NULL
lymphocytes	NULL
are	NULL
reduced	NULL
during	NULL
transition	NULL
from	NULL
G	NULL
,	NULL
/G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
remain	NULL
low	NULL
throughout	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
during	NULL
the	NULL
course	NULL
of	NULL
our	NULL
investigation	NULL
,	NULL
we	NULL
found	NULL
that	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
were	NULL
significantly	NULL
induced	NULL
when	NULL
cycling	NULL
PBT	NULL
cells	NULL
were	NULL
restimu-lated	NULL
with	NULL
OKT3	NULL
,	NULL
PMA	NULL
plus	NULL
PHA	NULL
,	NULL
or	NULL
ION	NULL
or	NULL
OKT3	NULL
.	NULL

This	NULL
was	NULL
in	NULL
contrast	NULL
to	NULL
resting	NULL
PBMCs	NULL
,	NULL
which	NULL
lost	NULL
RXRa	NULL
expression	NULL
after	NULL
activation	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
set	NULL
out	NULL
to	NULL
investigate	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
actively	NULL
dividing	NULL
and	NULL
cycling	NULL
normal	NULL
PBT	NULL
cells	NULL
and	NULL
also	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
cell	NULL
lines	NULL
(	NULL
Jurkat	NULL
and	NULL
SupT13	NULL
)	NULL
,	NULL
after	NULL
in	NULL
vitro	NULL
activation	NULL
by	NULL
OKT3	NULL
,	NULL
PMA	NULL
plus	NULL
PHA	NULL
,	NULL
or	NULL
0022-1767/00/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
4218	NULL
REGULATION	NULL
OF	NULL
RXRa	NULL
EXPRESSION	NULL
DURING	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
ION	NULL
or	NULL
OKT3	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
expression	NULL
were	NULL
significantly	NULL
increased	NULL
in	NULL
these	NULL
cells	NULL
after	NULL
these	NULL
treatments	NULL
.	NULL

The	NULL
accumulated	NULL
RXRa	NULL
was	NULL
found	NULL
to	NULL
be	NULL
transcriptionally	NULL
inactive	NULL
,	NULL
and	NULL
the	NULL
activation	NULL
resulted	NULL
in	NULL
the	NULL
silencing	NULL
of	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

We	NULL
provide	NULL
evidence	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
JNK	NULL
and	NULL
not	NULL
the	NULL
ERK	NULL
pathway	NULL
inhibits	NULL
the	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
ERK	NULL
pathway	NULL
was	NULL
found	NULL
to	NULL
increase	NULL
the	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
when	NULL
both	NULL
were	NULL
activated	NULL
simultaneously	NULL
,	NULL
JNK	NULL
pathway	NULL
was	NULL
dominant	NULL
over	NULL
ERK	NULL
pathway	NULL
and	NULL
resulted	NULL
in	NULL
inhibition	NULL
of	NULL
RXRE-mediated	NULL
gene	NULL
activation	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
a	NULL
dual	NULL
regulatory	NULL
control	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
and	NULL
cycling	NULL
T	NULL
lymphocytes	NULL
and	NULL
indicate	NULL
a	NULL
dynamic	NULL
balance	NULL
between	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
in	NULL
modulating	NULL
RXRE-mediated	NULL
transactivation	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cells	NULL
and	NULL
treatments	NULL
Human	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
Jurkat	NULL
cell	NULL
line	NULL
(	NULL
clone	NULL
E6-1	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
.	NULL

Human	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
Sup	NULL
T13	NULL
cell	NULL
line	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
Holden	NULL
T.	NULL
Maecker	NULL
(	NULL
Stanford	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Human	NULL
PBMCs	NULL
,	NULL
obtained	NULL
by	NULL
lymphapheresis	NULL
of	NULL
healthy	NULL
donors	NULL
,	NULL
were	NULL
purified	NULL
by	NULL
Ficoll	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Purified	NULL
PBMCs	NULL
(	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
PHA	NULL
and	NULL
IL-2	NULL
for	NULL
4	NULL
days	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
mM	NULL
HEPES	NULL
buffer	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
60	NULL
pg/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
FBS	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
medium	NULL
to	NULL
remove	NULL
PHA	NULL
and	NULL
maintained	NULL
in	NULL
IL-2	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
these	NULL
cells	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
proliferating	NULL
PBT	NULL
cells	NULL
.	NULL

PBT	NULL
cells	NULL
were	NULL
98	NULL
%	NULL
CD3-positive	NULL
as	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Jurkat	NULL
and	NULL
SupT13	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
.	NULL

Anti-CD3	NULL
Ab	NULL
,	NULL
OKT3	NULL
(	NULL
Ortho-Biotech	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
was	NULL
used	NULL
for	NULL
immobilization	NULL
at	NULL
10	NULL
in	NULL
PBS	NULL
at	NULL
37°C	NULL
for	NULL
3-5	NULL
h.	NULL
PHA	NULL
,	NULL
PMA	NULL
,	NULL
ION	NULL
,	NULL
and	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
(	NULL
9-CRA	NULL
)	NULL
,	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
and	NULL
were	NULL
used	NULL
at	NULL
2.5	NULL
ug/tal	NULL
,	NULL
50	NULL
ng/ml	NULL
,	NULL
400	NULL
ng/ml	NULL
,	NULL
and	NULL
1	NULL
M	NULL
,	NULL
respectively	NULL
.	NULL

Recombinant	NULL
IL-2	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
was	NULL
used	NULL
at	NULL
20	NULL
U/ml	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
ascomycin	NULL
(	NULL
an	NULL
analogue	NULL
of	NULL
FK506	NULL
;	NULL
Biomol	NULL
,	NULL
Plymouth	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
actinomycin	NULL
D	NULL
(	NULL
Act	NULL
D	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
PD98059	NULL
(	NULL
Calbiochem	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
were	NULL
used	NULL
at	NULL
1.5	NULL
pg/ml	NULL
,	NULL
50	NULL
nM	NULL
,	NULL
2.5pug/ml	NULL
,	NULL
and	NULL
50	NULL
uM	NULL
,	NULL
respectively	NULL
.	NULL

RNase	NULL
protection	NULL
assay	NULL
RNase	NULL
protection	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
29	NULL
)	NULL
,	NULL
using	NULL
a	NULL
RiboQuant	NULL
MultiProbe	NULL
RNase	NULL
protection	NULL
assay	NULL
system	NULL
kit	NULL
and	NULL
probes	NULL
containing	NULL
human	NULL
IL-2	NULL
,	NULL
GAPDH	NULL
,	NULL
and	NULL
L32	NULL
cDNA	NULL
sequences	NULL
(	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
RXRa	NULL
probe	NULL
was	NULL
generated	NULL
from	NULL
pNotA/T7	NULL
plasmid	NULL
(	NULL
5	NULL
Prime-	NULL
>	NULL
3	NULL
Prime	NULL
,	NULL
Boulder	NULL
,	NULL
CO	NULL
)	NULL
in	NULL
which	NULL
a	NULL
302-bp	NULL
PCR	NULL
fragment	NULL
of	NULL
RXRa	NULL
cDNA	NULL
was	NULL
cloned	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

All	NULL
cDNAs	NULL
were	NULL
transcribed	NULL
in	NULL
a	NULL
single	NULL
tube	NULL
using	NULL
T7	NULL
RNA	NULL
polymerase	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

RNase	NULL
protection	NULL
was	NULL
performed	NULL
using	NULL
6-10	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
,	NULL
and	NULL
the	NULL
products	NULL
were	NULL
resolved	NULL
in	NULL
8	NULL
M	NULL
urea/6	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Dried	NULL
gels	NULL
were	NULL
scanned	NULL
,	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
;	NULL
Fuji	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
and	NULL
also	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

Semiquantitative	NULL
RT-PCR	NULL
RT-PCR	NULL
was	NULL
performed	NULL
to	NULL
quantitate	NULL
RXRa	NULL
mRNA	NULL
using	NULL
the	NULL
primers	NULL
and	NULL
PCR	NULL
conditions	NULL
described	NULL
previously	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
Twenty-five	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
was	NULL
electrophoresed	NULL
in	NULL
a	NULL
10	NULL
%	NULL
NuPAGE	NULL
Bis	NULL
Tris	NULL
Gel	NULL
using	NULL
NuPAGE	NULL
MOPS-SDS	NULL
running	NULL
buffer	NULL
(	NULL
NOVEX	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
using	NULL
XCell	NULL
Blot	NULL
Module	NULL
(	NULL
NOVEX	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
blocked	NULL
with	NULL
Blocker	NULL
Blotto	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
4°C	NULL
with	NULL
1:1000	NULL
diluted	NULL
RXRa	NULL
(	NULL
D20	NULL
)	NULL
Ab	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech-nology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

RXRa	NULL
was	NULL
detected	NULL
using	NULL
the	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
from	NULL
Amersham	NULL
(	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
also	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
Abs	NULL
to	NULL
cyclin	NULL
B1	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
to	NULL
confirm	NULL
the	NULL
equal	NULL
loading	NULL
of	NULL
proteins	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
cyclin	NULL
B1	NULL
were	NULL
only	NULL
moderately	NULL
effected	NULL
by	NULL
various	NULL
treatments	NULL
,	NULL
except	NULL
treatments	NULL
involving	NULL
Act	NULL
D	NULL
,	NULL
where	NULL
there	NULL
was	NULL
nearly	NULL
complete	NULL
loss	NULL
of	NULL
cyclin	NULL
B1	NULL
protein	NULL
.	NULL

However	NULL
,	NULL
equal	NULL
loading	NULL
was	NULL
also	NULL
confirmed	NULL
in	NULL
samples	NULL
treated	NULL
with	NULL
Act	NULL
D	NULL
by	NULL
staining	NULL
the	NULL
gel	NULL
with	NULL
a	NULL
protein	NULL
stain	NULL
.	NULL

EMSA	NULL
The	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
RXRs	NULL
was	NULL
studied	NULL
by	NULL
EMSA	NULL
using	NULL
oligonu-cleotides	NULL
corresponding	NULL
to	NULL
cellular	NULL
retinol	NULL
binding	NULL
protein	NULL
type	NULL
II	NULL
(	NULL
CRBPII	NULL
)	NULL
RXRE	NULL
,	NULL
AGCTTCAGGTCAGAGGTCAGAGAGCT	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
1.0	NULL
pg	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
5	NULL
mM	NULL
HEPES	NULL
,	NULL
100	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
%	NULL
milk	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
10	NULL
pl	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
5	NULL
X	NULL
10+	NULL
cpm	NULL
of	NULL
°°P	NULL
end-labeled	NULL
probe	NULL
for	NULL
20-30	NULL
min	NULL
at	NULL
room	NULL
temper-ature	NULL
.	NULL

For	NULL
the	NULL
competition	NULL
experiment	NULL
,	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
was	NULL
added	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
°°P	NULL
end-labeled	NULL
probe	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
in	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
dried	NULL
gels	NULL
were	NULL
scanned	NULL
for	NULL
quantitation	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
;	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

Nuclear	NULL
run-on	NULL
transcription	NULL
assay	NULL
Nuclear	NULL
run-on	NULL
was	NULL
performed	NULL
with	NULL
Jurkat	NULL
cells	NULL
by	NULL
the	NULL
procedure	NULL
described	NULL
previously	NULL
(	NULL
29	NULL
)	NULL
.	NULL

JNK	NULL
and	NULL
ERK	NULL
assays	NULL
Cells	NULL
were	NULL
lysed	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
EGTA	NULL
,	NULL
40	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
1	NULL
tablet/50	NULL
ml	NULL
protease	NULL
inhibitor	NULL
cocktail	NULL
(	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
4°C	NULL
.	NULL

One-hundred	NULL
micrograms	NULL
of	NULL
supernatant	NULL
protein	NULL
were	NULL
treated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
anti-JNK-1	NULL
or	NULL
anti-ERK-1	NULL
Ab	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
500	NULL
pl	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
,	NULL
50	NULL
ul	NULL
of	NULL
protein	NULL
A	NULL
beads	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
two	NULL
times	NULL
with	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
and	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
and	NULL
finally	NULL
with	NULL
kinase	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
10	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
20	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
0.1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
.	NULL

Kinase	NULL
reaction	NULL
was	NULL
performed	NULL
for	NULL
20	NULL
min	NULL
at	NULL
30°C	NULL
in	NULL
30	NULL
pl	NULL
kinase	NULL
buffer	NULL
containing	NULL
20	NULL
M	NULL
cold	NULL
ATP	NULL
,	NULL
2	NULL
uCi	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
ATP	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
GST-c-Jun	NULL
(	NULL
1-79	NULL
)	NULL
for	NULL
JNK	NULL
or	NULL
myelin	NULL
basic	NULL
protein	NULL
for	NULL
ERK	NULL
assay	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
SDS	NULL
loading	NULL
buffer	NULL
,	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
electrophoresed	NULL
in	NULL
a	NULL
10	NULL
%	NULL
NuPAGE	NULL
Bis	NULL
Tris	NULL
Gel	NULL
using	NULL
NuPAGE	NULL
MOPS-SDS	NULL
running	NULL
buffer	NULL
(	NULL
NOVEX	NULL
)	NULL
.	NULL

The	NULL
dried	NULL
gels	NULL
were	NULL
scanned	NULL
for	NULL
quantitation	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
;	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

Transfections	NULL
The	NULL
effect	NULL
of	NULL
OKT3	NULL
and	NULL
PMA	NULL
+	NULL
PHA	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
RXRa	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
studied	NULL
by	NULL
transfection	NULL
using	NULL
RXRE-containing	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
,	NULL
CRBPI-TK-Luc	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
K.	NULL
Ozato	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
or	NULL
TATA-DR1-Luc	NULL
.	NULL

Both	NULL
these	NULL
plasmids	NULL
contained	NULL
RXRE	NULL
response	NULL
element	NULL
from	NULL
CRBPII	NULL
promoter	NULL
(	NULL
30	NULL
)	NULL
and	NULL
showed	NULL
similar	NULL
activity	NULL
in	NULL
transfection	NULL
assays	NULL
.	NULL

TATA-DR1-M-Luc	NULL
plasmid	NULL
was	NULL
used	NULL
as	NULL
mutant	NULL
RXRE-containing	NULL
plasmid	NULL
.	NULL

TATA-DR1-Luc	NULL
and	NULL
TATA-DR1-M-Luc	NULL
plasmids	NULL
were	NULL
constructed	NULL
by	NULL
cloning	NULL
CRBPHI	NULL
RXRE	NULL
sequence	NULL
and	NULL
CRBPI	NULL
RXRE	NULL
mutant	NULL
sequence	NULL
upstream	NULL
of	NULL
minimal	NULL
TATA	NULL
box	NULL
promoter	NULL
in	NULL
pGL3-Luc	NULL
basic	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pCMX-hRXRa	NULL
containing	NULL
the	NULL
cDNA	NULL
for	NULL
human	NULL
RXRa	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
R.	NULL
M.	NULL
Evans	NULL
(	NULL
The	NULL
Salk	NULL
Institute	NULL
of	NULL
Biological	NULL
Sci-ences	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

NFAT-Luc	NULL
plasmid	NULL
containing	NULL
trimerized	NULL
human	NULL
distal	NULL
IL-2	NULL
NFAT	NULL
site	NULL
inserted	NULL
into	NULL
IL-2	NULL
minimal	NULL
promoter	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
R.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

pFC-MEKK	NULL
(	NULL
en-coding	NULL
350-672	NULL
amino	NULL
acids	NULL
of	NULL
mouse	NULL
MEKK1	NULL
)	NULL
and	NULL
pFC-MEK1	NULL
(	NULL
encod-ing	NULL
mouse	NULL
MEK	NULL
1	NULL
with	NULL
serine	NULL
to	NULL
glutamic	NULL
acid	NULL
substitutions	NULL
at	NULL
218	NULL
and	NULL
222	NULL
positions	NULL
and	NULL
deletion	NULL
from	NULL
amino	NULL
acids	NULL
32	NULL
to	NULL
51	NULL
)	NULL
plasmids	NULL
,	NULL
used	NULL
as	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
and	NULL
MEK1	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
purchased	NULL
from	NULL
Stratagene	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

pSRa-MEKK1	NULL
(	NULL
K432	NULL
M	NULL
)	NULL
was	NULL
used	NULL
as	NULL
dominant	NULL
negative	NULL
MEKK1	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Munoz-Canoves	NULL
(	NULL
In-stitut	NULL
de	NULL
Recerca	NULL
Oncologica	NULL
,	NULL
Barcelona	NULL
,	NULL
Spain	NULL
)	NULL
.	NULL

AP1	NULL
(	NULL
PMA	NULL
)	NULL
-Luc	NULL
reporter	NULL
plasmid	NULL
was	NULL
purchased	NULL
from	NULL
Clontech	NULL
Laboratories	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
5-10	NULL
ug	NULL
of	NULL
each	NULL
plasmid	NULL
by	NULL
electropo-ration	NULL
using	NULL
a	NULL
Gene	NULL
Pulser	NULL
II	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
at	NULL
0.250	NULL
kV	NULL
and	NULL
975	NULL
uF	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
medium	NULL
for	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
and	NULL
time	NULL
periods	NULL
before	NULL
harvest	NULL
and	NULL
determination	NULL
of	NULL
luciferase	NULL
activity	NULL
using	NULL
the	NULL
Luciferase	NULL
Assay	NULL
System	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
to	NULL
protein	NULL
concentrations	NULL
in	NULL
the	NULL
extracts	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Results	NULL
Accumulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
lymphocytes	NULL
In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
PBT	NULL
and	NULL
two	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
cell	NULL
lines	NULL
(	NULL
Jurkat	NULL
and	NULL
SupT13	NULL
)	NULL
after	NULL
in	NULL
vitro	NULL
activation	NULL
by	NULL
either	NULL
OKT3	NULL
alone	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
+	NULL
OKT3	NULL
,	NULL
PMA	NULL
+	NULL
PHA	NULL
,	NULL
or	NULL
PMA	NULL
+	NULL
ION	NULL
.	NULL

To	NULL
study	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
mRNA	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
activation	NULL
agents	NULL
and	NULL
RNA	NULL
was	NULL
quantitated	NULL
by	NULL
RT-PCR	NULL
and	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

Fig	NULL
.	NULL

14	NULL
shows	NULL
the	NULL
RNase	NULL
protection	NULL
assay	NULL
used	NULL
for	NULL
quantitating	NULL
RXRa	NULL
and	NULL
IL-2	NULL
mRNAs	NULL
after	NULL
the	NULL
treatment	NULL
of	NULL
o	NULL
A	NULL
F	NULL
PMA	NULL
+	NULL
PHA	NULL
_	NULL
-	NULL
+	NULL
4+	NULL
4+	NULL
4	NULL
-	NULL
-	NULL
&	NULL
CsA	NULL
=	NULL
-	NULL
-	NULL
%	NULL
-	NULL
+	NULL
4	NULL
%	NULL
9-CRA	NULL
=	NULL
-	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
C	NULL
f	NULL
-	NULL
RXRo	NULL
an	NULL
dh	NULL
-	NULL
«	NULL
»	NULL
#	NULL
_/	NULL
©	NULL
-	NULL
>	NULL
|	NULL
/-	NULL
-	NULL
L-32	NULL
f	NULL
-	NULL
GAPDH	NULL
50-g	NULL
404	NULL
9	NULL
8	NULL
meam	NULL
Jurkat	NULL
®	NULL
zen	NULL
SupT13	NULL
a	NULL
c-=PBT	NULL
LW	NULL
39	NULL
.	NULL

<	NULL
2	NULL
TC	NULL
£	NULL
i	NULL
20-a	NULL
cC	NULL
P	NULL
4	NULL
3	NULL
A	NULL
2	NULL
12	NULL
2	NULL
P	NULL
2	NULL
)	NULL
2	NULL
B	NULL
104	NULL
A	NULL
2	NULL
|P	NULL
|	NULL
B	NULL
A	NULL
2	NULL
|	NULL
1B	NULL
|	NULL
IP	NULL
4	NULL
P	NULL
|	NULL
P	NULL
|	NULL
2	NULL
2	NULL
.	NULL

B	NULL
?	NULL

|	NULL
P	NULL
|	NULL
P	NULL
Al	NULL
&	NULL
Al	NULL
A	NULL
&	NULL
o-	NULL
201	NULL
7	NULL
A	NULL
|	NULL
1B	NULL
|	NULL
t	NULL
&	NULL
Z	NULL
<	NULL
$	NULL
6	NULL
f	NULL
s	NULL
i	NULL
E	NULL
&	NULL
OKT3+CsA	NULL
OKT3	NULL
+	NULL
PMA	NULL
PMA+PHA+CsA	NULL
PMA+PHA+9-CRA	NULL
BSS	NULL
PMA+PHA+Act	NULL
D	NULL
OKT3+CsA+9-CRA	NULL
PMA+PHA+CsA+9-CRA	NULL
FIGURE	NULL
1	NULL
.	NULL

Up-regulation	NULL
of	NULL
RXRa	NULL
in	NULL
activated	NULL
cycling	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
Total	NULL
RNA	NULL
isolated	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
as	NULL
indicated	NULL
for	NULL
24	NULL
h	NULL
,	NULL
was	NULL
subjected	NULL
to	NULL
RNase	NULL
protection	NULL
analysis	NULL
using	NULL
RXRa-	NULL
and	NULL
IL-2-specific	NULL
probes	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

GAPDH	NULL
and	NULL
L32	NULL
were	NULL
used	NULL
as	NULL
internal	NULL
controls	NULL
for	NULL
normalizing	NULL
the	NULL
RNA	NULL
concentrations	NULL
.	NULL

For	NULL
clarity	NULL
,	NULL
a	NULL
shorter	NULL
x-ray	NULL
exposure	NULL
time	NULL
is	NULL
shown	NULL
for	NULL
GAPDH	NULL
and	NULL
L32	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

B	NULL
,	NULL
Jurkat	NULL
,	NULL
SupT13	NULL
,	NULL
and	NULL
PBT	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
for	NULL
24	NULL
h	NULL
(	NULL
except	NULL
OKT3	NULL
treatment	NULL
of	NULL
Jurkat	NULL
and	NULL
PBT	NULL
,	NULL
which	NULL
was	NULL
done	NULL
for	NULL
48	NULL
h	NULL
)	NULL
,	NULL
and	NULL
RXRa	NULL
mRNA	NULL
was	NULL
quantitated	NULL
by	NULL
RT-PCR	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
SE	NULL
calculated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

OKT3	NULL
+	NULL
CsA	NULL
+	NULL
9-CRA	NULL
and	NULL
PMA	NULL
+	NULL
PHA	NULL
+	NULL
CsA	NULL
+	NULL
9-CRA	NULL
treatments	NULL
for	NULL
PBT	NULL
and	NULL
PMA	NULL
+	NULL
PHA	NULL
+	NULL
ActD	NULL
treatment	NULL
for	NULL
SupT13	NULL
were	NULL
not	NULL
performed	NULL
.	NULL

4219	NULL
Jurkat	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
for	NULL
24	NULL
h.	NULL
As	NULL
expected	NULL
,	NULL
IL-2	NULL
mRNA	NULL
showed	NULL
an	NULL
~50-fold	NULL
induction	NULL
during	NULL
PMA	NULL
+	NULL
PHA	NULL
treatment	NULL
.	NULL

There	NULL
was	NULL
also	NULL
a	NULL
marked	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
.	NULL

Time	NULL
kinetics	NULL
indicated	NULL
that	NULL
the	NULL
accumulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
began	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
after	NULL
the	NULL
dual	NULL
treatment	NULL
and	NULL
reached	NULL
its	NULL
peak	NULL
within	NULL
24	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
three	NULL
cell	NULL
types	NULL
showed	NULL
an	NULL
accumulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
(	NULL
7-	NULL
to	NULL
25-fold	NULL
)	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
,	NULL
PMA	NULL
+	NULL
OKT3	NULL
,	NULL
or	NULL
PMA	NULL
+	NULL
ION	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

OKT3	NULL
cross-linking	NULL
of	NULL
SupT13	NULL
cells	NULL
for	NULL
24	NULL
h	NULL
resulted	NULL
in	NULL
a	NULL
6-	NULL
to	NULL
10-fold	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
.	NULL

OKT3	NULL
cross-linking	NULL
of	NULL
Jurkat	NULL
and	NULL
PBT	NULL
induced	NULL
a	NULL
4-	NULL
to	NULL
6-fold	NULL
RXRa	NULL
mRNA	NULL
up-regulation	NULL
within	NULL
48	NULL
h.	NULL
In	NULL
addition	NULL
to	NULL
RXRa	NULL
«	NULL
,	NULL
all	NULL
cell	NULL
types	NULL
expressed	NULL
RXRB	NULL
,	NULL
RARa	NULL
,	NULL
and	NULL
RARy	NULL
mRNA	NULL
,	NULL
whereas	NULL
RXR	NULL
y	NULL
and	NULL
RARf	NULL
mRNA	NULL
were	NULL
undetectable	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
was	NULL
also	NULL
a	NULL
moderate	NULL
increase	NULL
(	NULL
2-	NULL
to	NULL
3-fold	NULL
)	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
RARa	NULL
mRNA	NULL
observed	NULL
during	NULL
dual	NULL
treatments	NULL
of	NULL
Jurkat	NULL
but	NULL
not	NULL
with	NULL
SupT13	NULL
or	NULL
PBT	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
RXR	NULL
$	NULL
and	NULL
RARy	NULL
mRNA	NULL
did	NULL
not	NULL
change	NULL
during	NULL
any	NULL
of	NULL
these	NULL
treatments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Western	NULL
blots	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
Jurkat	NULL
,	NULL
PBT	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
and	NULL
SupT13	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
cells	NULL
showed	NULL
that	NULL
there	NULL
was	NULL
a	NULL
significant	NULL
accumulation	NULL
of	NULL
RXRa	NULL
protein	NULL
during	NULL
activation	NULL
of	NULL
all	NULL
these	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
and	NULL
actively	NULL
dividing	NULL
PBT	NULL
cells	NULL
and	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
cell	NULL
lines	NULL
results	NULL
in	NULL
a	NULL
significant	NULL
induction	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
,	NULL
unlike	NULL
activation	NULL
of	NULL
resting	NULL
PBMCs	NULL
,	NULL
which	NULL
results	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
RXRa	NULL
expression	NULL
as	NULL
reported	NULL
earlier	NULL
(	NULL
29	NULL
)	NULL
.	NULL

A	NULL
OKT3	NULL
|	NULL
-	NULL
#	NULL
$	NULL
4	NULL
-o-	NULL
--	NULL
CsA	NULL
=	NULL
-	NULL
-	NULL
o	NULL
¥0-	NULL
4-	NULL
PMA+PHA	NULL
|	NULL
-	NULL
-	NULL
-o	NULL
o4+	NULL
+	NULL
4+	NULL
+	NULL
9-CRA	NULL
=-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
=-ActD	NULL
=	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
PC	NULL
-	NULL
\-	NULL
@	NULL
@	NULL
»	NULL
ome	NULL
®	NULL
rxno	NULL
Jurkat	NULL
~	NULL
UD	NULL
rnc	NULL
PBT	NULL
Sth	NULL
su	NULL
``	NULL
wa	NULL
Cyclin	NULL
B1	NULL
B	NULL
OoKT3	NULL
+	NULL
#	NULL
-	NULL
--	NULL
-CsA	NULL
-+-	NULL
+	NULL
--	NULL
PMA+PHA	NULL
|	NULL
-	NULL
-+	NULL
+	NULL
+-9-CRA	NULL
=-	NULL
--	NULL
-	NULL
$	NULL
-	NULL
PC	NULL
I	NULL
:	NULL
~	NULL
e	NULL
»	NULL
RXRo	NULL
:	NULL
SUPT13	NULL
UK	NULL
=	NULL
==	NULL
-~	NULL
2	NULL
%	NULL
ase	NULL
Cyclin	NULL
B1	NULL
FIGURE	NULL
2	NULL
.	NULL

Up-regulation	NULL
of	NULL
RXRa	NULL
protein	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
,	NULL
PBT	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
SupT13	NULL
(	NULL
B	NULL
)	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
for	NULL
24	NULL
h.	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
25	NULL
ug	NULL
of	NULL
protein	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
a	NULL
membrane	NULL
,	NULL
RXRa	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
RXRa	NULL
(	NULL
D20	NULL
)	NULL
Ab	NULL
using	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
from	NULL
Amersham	NULL
.	NULL

PC	NULL
,	NULL
In	NULL
vitro	NULL
translated	NULL
human	NULL
RXR	NULL
«	NULL
protein	NULL
used	NULL
as	NULL
positive	NULL
control	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
also	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
Abs	NULL
to	NULL
cyclin	NULL
B1	NULL
to	NULL
confirm	NULL
the	NULL
equal	NULL
loading	NULL
of	NULL
proteins	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

This	NULL
experiment	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
4220	NULL
REGULATION	NULL
OF	NULL
RXRa	NULL
EXPRESSION	NULL
DURING	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
CsA	NULL
augments	NULL
the	NULL
accumulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
To	NULL
understand	NULL
the	NULL
mechanism	NULL
of	NULL
RXRa	NULL
up-regulation	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
involved	NULL
pathways	NULL
similar	NULL
to	NULL
IL-2	NULL
pathways	NULL
and	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
RXRa	NULL
expression	NULL
.	NULL

Although	NULL
the	NULL
expected	NULL
inhibition	NULL
of	NULL
IL2	NULL
mRNA	NULL
synthesis	NULL
by	NULL
CsA	NULL
was	NULL
observed	NULL
,	NULL
this	NULL
was	NULL
not	NULL
accompanied	NULL
by	NULL
the	NULL
inhibition	NULL
of	NULL
RXRa	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Instead	NULL
,	NULL
there	NULL
was	NULL
a	NULL
2-	NULL
to	NULL
3-fold	NULL
further	NULL
enhancement	NULL
of	NULL
RXRa	NULL
mRNA	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
protein	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
in	NULL
Jurkat	NULL
and	NULL
SupT13	NULL
cells	NULL
when	NULL
activation	NULL
was	NULL
conducted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

Activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
did	NULL
not	NULL
further	NULL
increase	NULL
the	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
in	NULL
PBT	NULL
cells	NULL
.	NULL

Fur-thermore	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
activation	NULL
signals	NULL
,	NULL
CsA	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
in	NULL
any	NULL
of	NULL
the	NULL
cell	NULL
types	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
two	NULL
divergent	NULL
pathways	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
activation-induced	NULL
IL-2	NULL
synthesis	NULL
and	NULL
activation-associated	NULL
accumulation	NULL
of	NULL
RXRa	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
indicates	NULL
the	NULL
involvement	NULL
of	NULL
calcineurin	NULL
(	NULL
CN	NULL
)	NULL
signaling	NULL
pathways	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
with	NULL
ascomycin	NULL
(	NULL
an	NULL
FK506	NULL
analogue	NULL
and	NULL
inhibitor	NULL
of	NULL
CN	NULL
)	NULL
,	NULL
further	NULL
supporting	NULL
the	NULL
role	NULL
of	NULL
CN	NULL
signaling	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

9-CRA	NULL
prevents	NULL
activation-induced	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
up-regulation	NULL
9-CRA	NULL
prevented	NULL
the	NULL
activation-induced	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
in	NULL
all	NULL
the	NULL
three	NULL
cell	NULL
types	NULL
by	NULL
about	NULL
75	NULL
%	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
activation	NULL
signals	NULL
,	NULL
9-CRA	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
in	NULL
any	NULL
of	NULL
the	NULL
cell	NULL
types	NULL
.	NULL

9-CRA	NULL
was	NULL
also	NULL
found	NULL
to	NULL
abrogate	NULL
the	NULL
effect	NULL
of	NULL
CsA-induced	NULL
further	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
during	NULL
activation	NULL
in	NULL
Jurkat	NULL
and	NULL
SupT13	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

9-CRA-mediated	NULL
inhibition	NULL
of	NULL
RXRa	NULL
up-regulation	NULL
is	NULL
suggestive	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
retinoids	NULL
to	NULL
modulate	NULL
the	NULL
synthesis	NULL
of	NULL
their	NULL
own	NULL
receptor	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
IL-2	NULL
mRNA	NULL
were	NULL
also	NULL
nearly	NULL
completely	NULL
down-regulated	NULL
when	NULL
the	NULL
activation	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
9-CRA	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
during	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
To	NULL
define	NULL
the	NULL
transcriptional	NULL
or	NULL
posttranscriptional	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
transcription	NULL
of	NULL
RXRa	NULL
mRNA	NULL
8	NULL
h	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
and	NULL
PHA	NULL
,	NULL
using	NULL
the	NULL
nuclear	NULL
run-on	NULL
transcription	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
synthesis	NULL
showed	NULL
significant	NULL
increase	NULL
(	NULL
~5-fold	NULL
)	NULL
after	NULL
the	NULL
treat	NULL
PMA	NULL
+	NULL
PHA	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
CsA	NULL
-	NULL
-	NULL
+	NULL
-	NULL
+	NULL
9-CRA	NULL
-	NULL
-	NULL
-	NULL
+	NULL
+	NULL
Vector	NULL
-	NULL
'	NULL
_	NULL
B-Actin	NULL
-	NULL
PRIA	NULL
)	NULL
awp	NULL
aap	NULL
aao	NULL
aas	NULL
RXRo	NULL
-	NULL
sane	NULL
|	NULL
wae	NULL
ss	NULL
FIGURE	NULL
3	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Nuclear	NULL
run-on	NULL
was	NULL
performed	NULL
with	NULL
Jurkat	NULL
cells	NULL
treated	NULL
as	NULL
indicated	NULL
for	NULL
8	NULL
h.	NULL
Equivalent	NULL
amounts	NULL
of	NULL
radioactive	NULL
RNA	NULL
was	NULL
hybridized	NULL
to	NULL
nylon	NULL
membranes	NULL
on	NULL
which	NULL
10	NULL
pg	NULL
of	NULL
linearized	NULL
and	NULL
denatured	NULL
RXRa	NULL
,	NULL
B-actin	NULL
,	NULL
and	NULL
vector	NULL
(	NULL
without	NULL
insert	NULL
)	NULL
plasmids	NULL
were	NULL
slot	NULL
blotted	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
and	NULL
the	NULL
transcriptional	NULL
activity	NULL
was	NULL
quantitated	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
;	NULL
Fuji	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

ment	NULL
.	NULL

PMA	NULL
+	NULL
PHA	NULL
treatment	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
increased	NULL
the	NULL
RXR	NULL
mRNA	NULL
transcription	NULL
further	NULL
by	NULL
2-	NULL
to	NULL
3-fold	NULL
,	NULL
compared	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
treatment	NULL
alone	NULL
.	NULL

When	NULL
transcription	NULL
was	NULL
conducted	NULL
with	NULL
nuclei	NULL
from	NULL
cells	NULL
undergoing	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
9-CRA	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
RXR	NULL
mRNA	NULL
transcription	NULL
decreased	NULL
by	NULL
about	NULL
50	NULL
%	NULL
.	NULL

I-CRA	NULL
also	NULL
abrogated	NULL
the	NULL
effect	NULL
of	NULL
CsA-induced	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
transcription	NULL
by	NULL
nearly	NULL
50	NULL
%	NULL
.	NULL

The	NULL
transcriptional	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
was	NULL
further	NULL
investigated	NULL
using	NULL
transcriptional	NULL
inhibitor	NULL
Act	NULL
D.	NULL
There	NULL
was	NULL
up	NULL
to	NULL
90	NULL
%	NULL
inhibition	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
and	NULL
a	NULL
corresponding	NULL
decrease	NULL
in	NULL
protein	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
when	NULL
the	NULL
activation	NULL
was	NULL
conducted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
this	NULL
inhibitor	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
transcriptional	NULL
regulation	NULL
constitutes	NULL
the	NULL
major	NULL
control	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
.	NULL

Up-regulation	NULL
of	NULL
RXRa	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
RXRE	NULL
binding	NULL
activity	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
accumulation	NULL
of	NULL
RXRa	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBT	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
,	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CsA	NULL
or	NULL
9-CRA	NULL
,	NULL
for	NULL
RXRE	NULL
binding	NULL
activity	NULL
using	NULL
EMSA	NULL
.	NULL

The	NULL
extracts	NULL
from	NULL
the	NULL
PMA	NULL
+	NULL
PHA	NULL
and	NULL
PMA	NULL
+	NULL
PHA	NULL
+	NULL
CsA-treated	NULL
cells	NULL
exhibited	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
when	NULL
compared	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
9-CRA	NULL
did	NULL
not	NULL
show	NULL
any	NULL
significant	NULL
change	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
which	NULL
correlated	NULL
with	NULL
the	NULL
9-CRA-induced	NULL
inhibition	NULL
of	NULL
RXRa	NULL
up-regulation	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
activation-induced	NULL
accumulation	NULL
of	NULL
RXRa	NULL
protein	NULL
is	NULL
reflected	NULL
in	NULL
a	NULL
corresponding	NULL
increase	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

o	NULL
PMA+PHA—+++++§	NULL
9-CRA	NULL
--	NULL
+	NULL
-	NULL
-	NULL
-	NULL
<	NULL
CsA	NULL
-	NULL
-	NULL
-	NULL
+	NULL
-	NULL
-	NULL
8	NULL
SC	NULL
--	NULL
-	NULL
-+-	NULL
9	NULL
NSC	NULL
--	NULL
-	NULL
-	NULL
-	NULL
+	NULL
a	NULL
Wil	NULL
U	NULL
|	NULL
FIGURE	NULL
4	NULL
.	NULL

Up-regulation	NULL
of	NULL
RXRE	NULL
binding	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBT	NULL
,	NULL
treated	NULL
as	NULL
indicated	NULL
for	NULL
24	NULL
h	NULL
,	NULL
were	NULL
subjected	NULL
to	NULL
EMSA	NULL
using	NULL
CRBPIHI	NULL
probe	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
in	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
scanned	NULL
for	NULL
quantitation	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
;	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

SC	NULL
,	NULL
Specific	NULL
competitor	NULL
;	NULL
NSC	NULL
,	NULL
non-specific	NULL
competitor	NULL
.	NULL

This	NULL
experiment	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Inhibition	NULL
of	NULL
RXRE-mediated	NULL
transcription	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
To	NULL
investigate	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
accumulated	NULL
RXRa	NULL
protein	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
PMA	NULL
+	NULL
PHA	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
RXRE	NULL
containing	NULL
promoter	NULL
was	NULL
studied	NULL
by	NULL
transfection	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
TATA-DR1-Luc	NULL
or	NULL
TATA-DR1-M-Luc	NULL
plasmid	NULL
for	NULL
24-36	NULL
h	NULL
and	NULL
then	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
or	NULL
CsA	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
there	NULL
was	NULL
about	NULL
75	NULL
%	NULL
inhibition	NULL
of	NULL
the	NULL
RXRE-dependant	NULL
luciferase	NULL
activity	NULL
when	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
.	NULL

CsA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
PMA	NULL
+	NULL
PHA-induced	NULL
loss	NULL
of	NULL
RXRE	NULL
activity	NULL
.	NULL

We	NULL
also	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
activation	NULL
signals	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
RXRa	NULL
overexpressed	NULL
by	NULL
transfecting	NULL
Jurkat	NULL
cells	NULL
with	NULL
an	NULL
RXRa-express-ing	NULL
plasmid	NULL
,	NULL
pCMVX-hRXRa	NULL
,	NULL
along	NULL
with	NULL
TATA-DR1-Lue	NULL
for	NULL
24	NULL
h	NULL
and	NULL
then	NULL
treated	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
for	NULL
8	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
or	NULL
CsA	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
pCMVX-hRXRa-transfected	NULL
cells	NULL
showed	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
RXRE	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

5B	NULL
shows	NULL
that	NULL
this	NULL
activity	NULL
correlated	NULL
with	NULL
the	NULL
significant	NULL
levels	NULL
of	NULL
RXRa	NULL
protein	NULL
present	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

When	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
or	NULL
CsA	NULL
,	NULL
RXRE	NULL
activity	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
the	NULL
effect	NULL
on	NULL
the	NULL
constitutive	NULL
RXRE	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
,	NULL
even	NULL
though	NULL
significantly	NULL
higher	NULL
levels	NULL
of	NULL
RXRa	NULL
protein	NULL
were	NULL
present	NULL
in	NULL
PMA	NULL
+	NULL
PHA-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Transfection	NULL
A	NULL
CS	NULL
TATA-DR1-Lue	NULL
E3	NULL
TATA-DR1-Luc+RXRo	NULL
meam	NULL
TATA-DR1-M-Luc	NULL
eeea	NULL
NFAT-Luc	NULL
ho	NULL
A	NULL
[	NULL
+	NULL
]	NULL
0	NULL
o	NULL
o	NULL
o	NULL
o	NULL
a	NULL
o	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
(	NULL
x10°	NULL
)	NULL
c	NULL
©	NULL
)	NULL
10	NULL
A	NULL
(	NULL
_..	NULL
0	NULL
ﬂ	NULL
E	NULL
<	NULL
<	NULL
&	NULL
2	NULL
C	NULL
4	NULL
e	NULL
€	NULL
5	NULL
<	NULL
£	NULL
RJ	NULL
&	NULL
&	NULL
C	NULL
+	NULL
S	NULL
6	NULL
S	NULL
&	NULL
.	NULL

c.	NULL
TAT-DRI-Lue	NULL
+	NULL
+	NULL
+	NULL
pCMX-hRXRa	NULL
-	NULL
+	NULL
+	NULL
PMA	NULL
+	NULL
PHA	NULL
-	NULL
-	NULL
+	NULL
RXRa	NULL
-	NULL
<	NULL
am	NULL
Fold	NULL
Luc	NULL
activity	NULL
1	NULL
4	NULL
1	NULL
FIGURE	NULL
5	NULL
.	NULL

Inhibition	NULL
of	NULL
RXRE-driven	NULL
transcriptional	NULL
activity	NULL
during	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
TATA-DR1-Luc	NULL
or	NULL
TATA-DR1-M-Luc	NULL
or	NULL
TATA-DR1-Luc	NULL
+	NULL
pCMX-hRXRa	NULL
or	NULL
NFAT-Luc	NULL
for	NULL
24	NULL
h	NULL
and	NULL
then	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
or	NULL
CsA	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
24-h	NULL
transfected	NULL
cells	NULL
were	NULL
also	NULL
treated	NULL
with	NULL
10ug/ml	NULL
OKT3	NULL
,	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
,	NULL
for	NULL
16	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
and	NULL
Luciferase	NULL
activity	NULL
measured	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
SE	NULL
calculated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

B	NULL
,	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
TATA-DR1-Luc	NULL
and	NULL
TATA-DR1-Lue	NULL
+	NULL
pCMX-hRXRa	NULL
cotransfected	NULL
cells	NULL
after	NULL
8	NULL
h	NULL
of	NULL
indicated	NULL
treatments	NULL
and	NULL
analyzed	NULL
for	NULL
RXRa	NULL
protein	NULL
by	NULL
Western	NULL
blotting	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
values	NULL
of	NULL
luciferase	NULL
activity	NULL
corresponding	NULL
to	NULL
each	NULL
treatment	NULL
are	NULL
expressed	NULL
in	NULL
folds	NULL
;	NULL
the	NULL
constitutive	NULL
DR1	NULL
luciferase	NULL
activity	NULL
was	NULL
given	NULL
a	NULL
value	NULL
of	NULL
1	NULL
.	NULL

4221	NULL
with	NULL
TATA-DR-1-M-Luc	NULL
plasmid	NULL
did	NULL
not	NULL
result	NULL
in	NULL
any	NULL
significant	NULL
luciferase	NULL
activity	NULL
,	NULL
and	NULL
PMA	NULL
+	NULL
PHA	NULL
,	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
CsA	NULL
or	NULL
9-CRA	NULL
,	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
this	NULL
activity	NULL
.	NULL

Induction	NULL
of	NULL
NFAT	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
accumulated	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
was	NULL
studied	NULL
in	NULL
parallel	NULL
as	NULL
an	NULL
activation	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

There	NULL
was	NULL
about	NULL
140-fold	NULL
increase	NULL
in	NULL
the	NULL
NFAT-driven	NULL
luciferase	NULL
activity	NULL
after	NULL
NFAT-Luc	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
when	NULL
the	NULL
activation	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
,	NULL
there	NULL
was	NULL
complete	NULL
loss	NULL
of	NULL
NFAT	NULL
promoter	NULL
activity	NULL
.	NULL

There	NULL
was	NULL
a	NULL
50	NULL
%	NULL
down-regulation	NULL
of	NULL
NFAT-driven	NULL
luciferase	NULL
activity	NULL
when	NULL
PMA	NULL
+	NULL
PHA	NULL
treatment	NULL
was	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
9-CRA	NULL
.	NULL

JNK	NULL
pathway	NULL
inhibits	NULL
and	NULL
ERK	NULL
pathway	NULL
stimulates	NULL
RXRE-mediated	NULL
transcription	NULL
Because	NULL
T	NULL
cell	NULL
activation	NULL
is	NULL
known	NULL
to	NULL
trigger	NULL
the	NULL
activation	NULL
of	NULL
MAP	NULL
kinases	NULL
,	NULL
which	NULL
include	NULL
JNK	NULL
and	NULL
ERK	NULL
cascades	NULL
,	NULL
we	NULL
explored	NULL
the	NULL
possibility	NULL
of	NULL
the	NULL
role	NULL
of	NULL
these	NULL
kinases	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
activates	NULL
both	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

These	NULL
pathways	NULL
are	NULL
also	NULL
activated	NULL
by	NULL
expressing	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
MEKK1	NULL
inhibits	NULL
the	NULL
JNK	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

When	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
plasmid	NULL
,	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
pCMVX-hRXRa	NULL
«	NULL
,	NULL
there	NULL
was	NULL
a	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
both	NULL
ligand	NULL
dependent	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
independent	NULL
RXRE-driven	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Under	NULL
similar	NULL
experimental	NULL
conditions	NULL
,	NULL
there	NULL
was	NULL
a	NULL
marked	NULL
stimulation	NULL
of	NULL
AP-1-driven	NULL
luciferase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
when	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
MEKK1	NULL
and	NULL
AP1-Luc	NULL
reporter	NULL
plasmids	NULL
as	NULL
a	NULL
control	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
MEKK1	NULL
,	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
pCMVX-hRXRa	NULL
,	NULL
increased	NULL
the	NULL
RXRE-driven	NULL
transcription	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
JNK	NULL
pathway	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

To	NULL
rule	NULL
out	NULL
the	NULL
contribution	NULL
of	NULL
ERK	NULL
activation	NULL
in	NULL
the	NULL
MEKK1-induced	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
,	NULL
MEKK1	NULL
transfection	NULL
was	NULL
also	NULL
conducted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
MEK	NULL
inhibitor	NULL
PD98059	NULL
.	NULL

Unexpectedly	NULL
,	NULL
there	NULL
was	NULL
an	NULL
additive	NULL
effect	NULL
on	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
by	NULL
MEKK1	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
MEK	NULL
inhibitor	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
was	NULL
modest	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PD98059	NULL
without	NULL
MEKKI1	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
unlike	NULL
JNK	NULL
pathway	NULL
,	NULL
ERK	NULL
pathway	NULL
positively	NULL
regulates	NULL
the	NULL
RXRE-driven	NULL
transcription	NULL
.	NULL

This	NULL
observation	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
transfecting	NULL
Jurkat	NULL
cells	NULL
with	NULL
constitutively	NULL
active	NULL
MEK	NULL
1	NULL
plasmid	NULL
,	NULL
which	NULL
activates	NULL
ERK	NULL
pathway	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

6D	NULL
shows	NULL
that	NULL
there	NULL
was	NULL
a	NULL
dose-dependent	NULL
increase	NULL
in	NULL
the	NULL
RXRE-driven	NULL
transcription	NULL
with	NULL
constitutively	NULL
active	NULL
MEK	NULL
1	NULL
plasmid	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
under	NULL
the	NULL
dual	NULL
control	NULL
of	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
and	NULL
they	NULL
exert	NULL
opposite	NULL
effects	NULL
on	NULL
the	NULL
RXRE-dependent	NULL
gene	NULL
transcription	NULL
.	NULL

JNK	NULL
pathway	NULL
is	NULL
dominant	NULL
over	NULL
ERK	NULL
pathway	NULL
in	NULL
modulating	NULL
RXRE-driven	NULL
transcription	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
Given	NULL
that	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
activates	NULL
both	NULL
ERK	NULL
and	NULL
JNK	NULL
pathways	NULL
and	NULL
our	NULL
observation	NULL
that	NULL
activation	NULL
leads	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
,	NULL
it	NULL
can	NULL
be	NULL
speculated	NULL
that	NULL
,	NULL
when	NULL
both	NULL
pathways	NULL
are	NULL
activated	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
JNK	NULL
pathway	NULL
is	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
4222	NULL
FIGURE	NULL
6	NULL
.	NULL

-	NULL
Opposite	NULL
effects	NULL
of	NULL
MEKK1	NULL
and	NULL
MEK1	NULL
on	NULL
RXRE-driven	NULL
transcriptional	NULL
activity	NULL
.	NULL

JNK	NULL
and	NULL
ERK	NULL
assays	NULL
were	NULL
performed	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
with	NULL
extracts	NULL
from	NULL
PMA	NULL
+	NULL
PHA-treated	NULL
Jurkat	NULL
cells	NULL
and	NULL
extracts	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
indicated	NULL
plasmids	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
TATA-	NULL
DR1-Luc	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
or	NULL
AP-1-Luc	NULL
(	NULL
C	NULL
)	NULL
plasmids	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
indicated	NULL
concentrations	NULL
of	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
(	NULL
MEKK1DA	NULL
)	NULL
or	NULL
dominant	NULL
negative	NULL
MEKK1	NULL
(	NULL
MEKK1DN	NULL
)	NULL
(	NULL
B	NULL
)	NULL
or	NULL
constitutively	NULL
active	NULL
MEK1	NULL
(	NULL
MEK1DA	NULL
)	NULL
plasmid	NULL
(	NULL
D	NULL
)	NULL
or	NULL
empty	NULL
vector	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
PD98059	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
50	NULL
uM	NULL
after	NULL
24	NULL
h	NULL
of	NULL
transfection	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
B*	NULL
354	NULL
TATA-DR1-Luc	NULL
m	NULL
a	NULL
to	NULL
F	NULL
i	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
(	NULL
x10°	NULL
)	NULL
a	NULL
3	NULL
6	NULL
a	NULL
107	NULL
y	NULL
36	NULL
h	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
%	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

s	NULL
é	NULL
The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
é	NULL
|	NULL
independent	NULL
experiments	NULL
with	NULL
SE	NULL
calcu-	NULL
**	NULL
4	NULL
o	NULL
ta	NULL
o	NULL
a	NULL
o	NULL
a	NULL
e	NULL
o	NULL
9	NULL
o	NULL
lated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

é	NULL
‘	NULL
ggeeeeeé	NULL
¢	NULL
8	NULL
q	NULL
9	NULL
98	NULL
6	NULL
D	NULL
O	NULL
D	NULL
a	NULL
4-4	NULL
i	NULL
%	NULL
i	NULL
%	NULL
,	NULL
ais	NULL
999	NULL
p	NULL
9	NULL
1	NULL
it	NULL
0	NULL
o	NULL
9	NULL
0	NULL
0	NULL
Nig	NULL
iP	NULL
&	NULL
$	NULL
o	NULL
a.	NULL
dominant	NULL
over	NULL
ERK	NULL
pathway	NULL
in	NULL
modulating	NULL
RXRE-driven	NULL
transcription	NULL
.	NULL

To	NULL
test	NULL
this	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
TATA-DR1-Luc	NULL
reporter	NULL
vector	NULL
and	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
plasmid	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
constitutively	NULL
active	NULL
MEK1	NULL
plasmid	NULL
.	NULL

Similarly	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
TATA-DR1-Luc	NULL
reporter	NULL
vector	NULL
and	NULL
constitutively	NULL
active	NULL
MEK1	NULL
plasmid	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
plasmid	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
demonstrate	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
by	NULL
MEKK1	NULL
could	NULL
only	NULL
be	NULL
partially	NULL
reversed	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
constitutively	NULL
active	NULL
MEK1	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
up-regulation	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
by	NULL
MEK1	NULL
was	NULL
completely	NULL
inhibited	NULL
by	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
,	NULL
when	NULL
activated	NULL
alone	NULL
,	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
have	NULL
opposite	NULL
effect	NULL
on	NULL
RXRE-driven	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
when	NULL
activated	NULL
together	NULL
,	NULL
JNK-dependent	NULL
inhibition	NULL
becomes	NULL
dominant	NULL
over	NULL
ERK-mediated	NULL
up-regulation	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
Abs	NULL
to	NULL
CD3	NULL
induce	NULL
activation	NULL
of	NULL
ERK	NULL
and	NULL
not	NULL
of	NULL
JNK	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
CD3-induced	NULL
ERK	NULL
activation	NULL
would	NULL
result	NULL
in	NULL
the	NULL
increases	NULL
in	NULL
RXRE-dependent	NULL
transcription	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
9-CRA	NULL
,	NULL
following	NULL
transfection	NULL
with	NULL
TATA-DR1-Luc	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

54	NULL
show	NULL
that	NULL
there	NULL
was	NULL
no	NULL
increase	NULL
but	NULL
about	NULL
35	NULL
%	NULL
loss	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
following	NULL
treatment	NULL
of	NULL
transfected	NULL
cells	NULL
with	NULL
OKT3	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
we	NULL
assayed	NULL
OKT3	NULL
treated	NULL
Jurkat	NULL
cells	NULL
for	NULL
ERK	NULL
and	NULL
JNK	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
we	NULL
found	NULL
that	NULL
both	NULL
were	NULL
activated	NULL
although	NULL
ERK	NULL
was	NULL
activated	NULL
at	NULL
a	NULL
higher	NULL
level	NULL
than	NULL
JNK	NULL
.	NULL

Anti-CD3	NULL
induced	NULL
dual	NULL
sma	NULL
Z	NULL
0.1	NULL
ug	NULL
MEKK1DN	NULL
0.5	NULL
ug	NULL
MEKK1DN	NULL
poy	NULL
Z	NULL
REGULATION	NULL
OF	NULL
RXRa	NULL
EXPRESSION	NULL
DURING	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
A	NULL
a	NULL
O	NULL
Vector	NULL
[	NULL
MEK1	NULL
(	NULL
DA	NULL
)	NULL
(	NULL
oly	NULL
'	NULL
MEKK1	NULL
(	NULL
DA	NULL
)	NULL
MEKK1	NULL
(	NULL
DN	NULL
)	NULL
PMA+PHA	NULL
Negative	NULL
Control	NULL
_	NULL
_	NULL
wzzza	NULL
TATA-DR1-Luc	NULL
[	NULL
(	NULL
@	NULL
]	NULL
O	NULL
8	NULL
czzzn	NULL
AP-1-Luc	NULL
c	NULL
T	NULL
a	NULL
pp	NULL
.	NULL

ep..	NULL
Bome	NULL
rt	NULL
sss	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
(	NULL
x10°	NULL
)	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
(	NULL
x10°	NULL
)	NULL
8	NULL
sss	NULL
m	NULL
!	NULL

p	NULL
-	NULL
7	NULL
?	NULL

%	NULL
IK	NULL
m	NULL
$	NULL
?	NULL

A	NULL
al	NULL
#	NULL
2	NULL
55	NULL
A	NULL
¥	NULL
33	NULL
e	NULL
33	NULL
%	NULL
3333	NULL
S	NULL
$	NULL
$	NULL
HE	NULL
41161	NULL
activation	NULL
of	NULL
ERK	NULL
and	NULL
JNK	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
by	NULL
others	NULL
(	NULL
16	NULL
,	NULL
35	NULL
)	NULL
.	NULL

These	NULL
data	NULL
further	NULL
support	NULL
the	NULL
finding	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
inhibits	NULL
the	NULL
RXRE-dependent	NULL
transcription	NULL
and	NULL
JNK	NULL
effect	NULL
is	NULL
dominant	NULL
in	NULL
inhibiting	NULL
RXRE-mediated	NULL
transcription	NULL
,	NULL
when	NULL
both	NULL
JNK	NULL
and	NULL
ERK	NULL
are	NULL
activated	NULL
simultaneously	NULL
.	NULL

Relatively	NULL
lower	NULL
inhibition	NULL
of	NULL
RXRE-dependent	NULL
transcription	NULL
by	NULL
OKT3	NULL
as	NULL
compared	NULL
with	NULL
75	NULL
%	NULL
inhibition	NULL
induced	NULL
by	NULL
PMA	NULL
+	NULL
PHA	NULL
may	NULL
be	NULL
due	NULL
to	NULL
low	NULL
level	NULL
JNK	NULL
activation	NULL
by	NULL
anti-CD3	NULL
as	NULL
compared	NULL
with	NULL
treatment	NULL
with	NULL
PMA	NULL
+	NULL
PHA	NULL
.	NULL

Discussion	NULL
To	NULL
explore	NULL
the	NULL
role	NULL
of	NULL
retinoid	NULL
receptors	NULL
in	NULL
T	NULL
cell	NULL
biology	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
and	NULL
its	NULL
function	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
RXRa	NULL
«	NULL
levels	NULL
in	NULL
resting	NULL
human	NULL
PBMCs	NULL
are	NULL
reduced	NULL
following	NULL
activation	NULL
and	NULL
transition	NULL
from	NULL
G	NULL
,	NULL
/G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
the	NULL
low	NULL
levels	NULL
are	NULL
maintained	NULL
throughout	NULL
active	NULL
cell	NULL
division	NULL
and	NULL
proliferation	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
is	NULL
modulated	NULL
differently	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
expression	NULL
were	NULL
significantly	NULL
increased	NULL
in	NULL
these	NULL
cells	NULL
after	NULL
activation	NULL
,	NULL
unlike	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
PBMCs	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
RXRa	NULL
expression	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
data	NULL
suggest	NULL
the	NULL
existence	NULL
of	NULL
dual	NULL
regulatory	NULL
signals	NULL
that	NULL
control	NULL
RXRa	NULL
expression	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
and	NULL
cycling	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

These	NULL
signals	NULL
have	NULL
distinct	NULL
characteristics	NULL
;	NULL
the	NULL
activation	NULL
signals	NULL
that	NULL
lead	NULL
to	NULL
G/G	NULL
,	NULL
to	NULL
S	NULL
switch	NULL
and	NULL
proliferation	NULL
of	NULL
resting	NULL
cells	NULL
result	NULL
in	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
,	NULL
whereas	NULL
the	NULL
activation	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
45-	NULL
TATA-DR1-Lue	NULL
p	NULL
C	NULL
to	NULL
T.	NULL
m	NULL
T	NULL
ro	NULL
on	NULL
L	NULL
ho	NULL
O	NULL
L	NULL
P	NULL
on	NULL
L	NULL
%	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
(	NULL
x10°	NULL
)	NULL
R	NULL
FZ	NULL
W	NULL
sy	NULL
Gifs	NULL
ss	NULL
o	NULL
MEK1DA	NULL
MEK1DA+	NULL
2.5	NULL
ug	NULL
MEKK1DA	NULL
MEK1DA+5.0	NULL
ug	NULL
MEKK1DA	NULL
MEKK1DA+2.5	NULL
ug	NULL
MEK1DA	NULL
MEKK1DA+5.0	NULL
ug	NULL
MEK1DA	NULL
FIGURE	NULL
7	NULL
.	NULL

Dominant	NULL
effect	NULL
of	NULL
MEKK1	NULL
expression	NULL
on	NULL
RXRE-driven	NULL
transcriptional	NULL
activity	NULL
during	NULL
coexpression	NULL
of	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
and	NULL
MEK1	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
pg	NULL
of	NULL
TATA-DR1-Luc	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
either	NULL
constitutively	NULL
active	NULL
MEKK1	NULL
or	NULL
MEK	NULL
1	NULL
plasmids	NULL
(	NULL
5	NULL
pg	NULL
)	NULL
and	NULL
indicated	NULL
concentrations	NULL
of	NULL
either	NULL
constitutively	NULL
active	NULL
MEK1	NULL
or	NULL
MEKK1	NULL
plasmids	NULL
,	NULL
respectively	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
36	NULL
h	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
SE	NULL
calculated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

signals	NULL
leading	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
cell	NULL
growth	NULL
of	NULL
the	NULL
cycling	NULL
T	NULL
cells	NULL
result	NULL
in	NULL
the	NULL
accumulation	NULL
of	NULL
RXRa	NULL
.	NULL

Although	NULL
the	NULL
physiological	NULL
relevance	NULL
of	NULL
accumulated	NULL
RXRa	NULL
is	NULL
not	NULL
yet	NULL
understood	NULL
,	NULL
fine	NULL
tuning	NULL
of	NULL
levels	NULL
of	NULL
RXRa	NULL
expression	NULL
may	NULL
have	NULL
important	NULL
immu-nological	NULL
consequences	NULL
in	NULL
the	NULL
positive	NULL
and	NULL
negative	NULL
selection	NULL
of	NULL
T	NULL
lymphocytes	NULL
and	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
lymphocyte-dependent	NULL
immune	NULL
responses	NULL
.	NULL

RXRs	NULL
are	NULL
known	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
as	NULL
promiscuous	NULL
heterodimerization	NULL
partners	NULL
in	NULL
modulating	NULL
the	NULL
activities	NULL
of	NULL
a	NULL
number	NULL
of	NULL
nuclear	NULL
receptors	NULL
,	NULL
which	NULL
include	NULL
RAR	NULL
(	NULL
36	NULL
)	NULL
,	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
vitamin	NULL
D	NULL
receptor	NULL
(	NULL
36	NULL
)	NULL
,	NULL
peroxisome	NULL
proliferator	NULL
activated	NULL
receptors	NULL
(	NULL
38	NULL
)	NULL
,	NULL
and	NULL
COUP-TF	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Dynamic	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
is	NULL
probably	NULL
an	NULL
important	NULL
mechanism	NULL
allowing	NULL
T	NULL
cells	NULL
to	NULL
calibrate	NULL
their	NULL
responses	NULL
to	NULL
different	NULL
levels	NULL
of	NULL
stimuli	NULL
.	NULL

To	NULL
gain	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
mechanism	NULL
of	NULL
RXRa	NULL
induction	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
involves	NULL
pathways	NULL
similar	NULL
to	NULL
IL-2	NULL
pathways	NULL
,	NULL
and	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
RXRa	NULL
expression	NULL
during	NULL
activation	NULL
.	NULL

There	NULL
was	NULL
a	NULL
significant	NULL
enhancement	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
when	NULL
activation	NULL
was	NULL
conducted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
,	NULL
although	NULL
under	NULL
similar	NULL
conditions	NULL
there	NULL
was	NULL
a	NULL
marked	NULL
inhibition	NULL
of	NULL
IL-2	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
two	NULL
divergent	NULL
pathways	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
activation-induced	NULL
IL-2	NULL
synthesis	NULL
and	NULL
activation-associated	NULL
accumulation	NULL
of	NULL
RXRa	NULL
.	NULL

Although	NULL
the	NULL
mechanism	NULL
of	NULL
CsA-induced	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
remains	NULL
unknown	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
a	NULL
link	NULL
between	NULL
the	NULL
pathways	NULL
that	NULL
regulate	NULL
RXRa	NULL
levels	NULL
and	NULL
pathways	NULL
involving	NULL
calmodulin-dependent	NULL
activation	NULL
of	NULL
serine-threonine	NULL
phosphatase	NULL
CN	NULL
(	NULL
40	NULL
)	NULL
.	NULL

4223	NULL
Activation	NULL
IL2	NULL
$	NULL
k_	NULL
:	NULL
A	NULL
©	NULL
OKT3	NULL
or	NULL
PMA/ION	NULL
HXRa	NULL
‘	NULL
Quiescent	NULL
T	NULL
Cell	NULL
B	NULL
Activation	NULL
IL2	NULL
*	NULL
OKT3	NULL
or	NULL
PMA/ION	NULL
RXRa	NULL
$	NULL
FIGURE	NULL
8	NULL
.	NULL

Dual	NULL
regulatory	NULL
control	NULL
of	NULL
RXRa	NULL
:	NULL
expression	NULL
during	NULL
activation	NULL
of	NULL
resting	NULL
and	NULL
cycling	NULL
T	NULL
lymphocytes	NULL
.	NULL

A	NULL
,	NULL
Quiescent	NULL
PBT	NULL
cells	NULL
(	NULL
which	NULL
are	NULL
in	NULL
G/G	NULL
,	NULL
phase	NULL
of	NULL
cell	NULL
cycle	NULL
)	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
in	NULL
vitro	NULL
treatment	NULL
with	NULL
T	NULL
cell	NULL
activation	NULL
agents	NULL
like	NULL
OKT3	NULL
or	NULL
PMA/ION	NULL
,	NULL
to	NULL
express	NULL
IL-2	NULL
and	NULL
proliferate	NULL
.	NULL

The	NULL
proliferating	NULL
T	NULL
cells	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
RXRa	NULL
:	NULL
as	NULL
compared	NULL
with	NULL
resting	NULL
cells	NULL
(	NULL
29	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Restimulation	NULL
of	NULL
actively	NULL
cycling	NULL
PBT	NULL
cells	NULL
or	NULL
T	NULL
lymphocyte	NULL
leukemia	NULL
cell	NULL
lines	NULL
leads	NULL
to	NULL
IL-2	NULL
expression	NULL
,	NULL
inhibition	NULL
of	NULL
proliferation	NULL
,	NULL
and	NULL
AICD	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
is	NULL
elevated	NULL
.	NULL

Cycling	NULL
T	NULL
Cell	NULL
9-CRA	NULL
is	NULL
a	NULL
ligand	NULL
for	NULL
RXRa	NULL
that	NULL
is	NULL
important	NULL
for	NULL
RXRE-mediated	NULL
transcription	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
immunomodula-tory	NULL
effect	NULL
.	NULL

Although	NULL
9-CRA	NULL
did	NULL
not	NULL
prevent	NULL
the	NULL
activation-induced	NULL
growth	NULL
inhibition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
it	NULL
surprisingly	NULL
prevented	NULL
the	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
.	NULL

9-CRA-mediated	NULL
and	NULL
transcriptionally	NULL
regulated	NULL
inhibition	NULL
of	NULL
RXRa	NULL
up-regulation	NULL
is	NULL
suggestive	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
retinoids	NULL
to	NULL
modulate	NULL
the	NULL
synthesis	NULL
of	NULL
their	NULL
own	NULL
receptors	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
such	NULL
inhibition	NULL
is	NULL
not	NULL
understood	NULL
and	NULL
may	NULL
involve	NULL
a	NULL
general	NULL
mechanism	NULL
rather	NULL
than	NULL
a	NULL
direct	NULL
effect	NULL
on	NULL
RXRa	NULL
.	NULL

Retinoids	NULL
have	NULL
been	NULL
known	NULL
to	NULL
antagonize	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
phorbol	NULL
esters	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
modulation	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
by	NULL
retinoids	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
their	NULL
influence	NULL
on	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
IL-2	NULL
mRNA	NULL
were	NULL
also	NULL
nearly	NULL
completely	NULL
down-regulated	NULL
when	NULL
the	NULL
activation	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
9-CRA	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
9-CRA-induced	NULL
inhibition	NULL
of	NULL
IL-2	NULL
up-regulation	NULL
remains	NULL
to	NULL
be	NULL
studied	NULL
and	NULL
could	NULL
possibly	NULL
involve	NULL
mechanisms	NULL
similar	NULL
to	NULL
RAR-selective	NULL
ligand-induced	NULL
down-regulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
reported	NULL
earlier	NULL
(	NULL
42	NULL
)	NULL
.	NULL

We	NULL
provide	NULL
evidence	NULL
that	NULL
RXRa	NULL
accumulated	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
is	NULL
transcriptionally	NULL
inactive	NULL
and	NULL
activation	NULL
leads	NULL
to	NULL
the	NULL
silencing	NULL
of	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
two	NULL
important	NULL
MAP	NULL
kinase	NULL
signaling	NULL
pathways	NULL
,	NULL
JNK	NULL
and	NULL
ERK	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
activated	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
15-18	NULL
,	NULL
35	NULL
,	NULL
43	NULL
)	NULL
,	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

To	NULL
the	NULL
best	NULL
of	NULL
our	NULL
knowledge	NULL
,	NULL
there	NULL
are	NULL
no	NULL
earlier	NULL
reports	NULL
of	NULL
MEKK1	NULL
or	NULL
MEK	NULL
1	NULL
pathways	NULL
regulating	NULL
the	NULL
transactivation	NULL
function	NULL
of	NULL
RXRa	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
role	NULL
of	NULL
other	NULL
pathways	NULL
regulating	NULL
the	NULL
RXRE-driven	NULL
transcription	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
our	NULL
data	NULL
provide	NULL
direct	NULL
evidence	NULL
that	NULL
JNK	NULL
pathway	NULL
inhibits	NULL
,	NULL
whereas	NULL
ERK	NULL
pathway	NULL
stimulates	NULL
,	NULL
RXRE-driven	NULL
transcription	NULL
,	NULL
and	NULL
JNK	NULL
pathway	NULL
is	NULL
dominant	NULL
over	NULL
ERK	NULL
pathway	NULL
when	NULL
both	NULL
are	NULL
simultaneously	NULL
activated	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
existence	NULL
,	NULL
in	NULL
the	NULL
T	NULL
cells	NULL
,	NULL
of	NULL
a	NULL
dynamic	NULL
balance	NULL
between	NULL
the	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
in	NULL
regulating	NULL
the	NULL
RXRE-driven	NULL
transactivation	NULL
function	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
has	NULL
shown	NULL
that	NULL
activation	NULL
of	NULL
JNK	NULL
pathway	NULL
and	NULL
inhibition	NULL
of	NULL
ERK	NULL
pathway	NULL
is	NULL
critical	NULL
for	NULL
apoptosis	NULL
in	NULL
rat	NULL
PC-12	NULL
pheochromocytoma	NULL
cells	NULL
,	NULL
and	NULL
ERK	NULL
activation	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
proliferation	NULL
and	NULL
survival	NULL
(	NULL
44	NULL
)	NULL
.	NULL

In	NULL
T	NULL
lymphocytes	NULL
,	NULL
ERK	NULL
and	NULL
p38	NULL
pathways	NULL
have	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
selection	NULL
,	NULL
respectively	NULL
(	NULL
45	NULL
)	NULL
.	NULL

TCR	NULL
engagement	NULL
and	NULL
treatment	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
4224	NULL
with	NULL
PMA	NULL
and	NULL
PHA	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
signals	NULL
leading	NULL
to	NULL
AICD	NULL
and	NULL
JNK	NULL
being	NULL
an	NULL
important	NULL
pathway	NULL
in	NULL
modulating	NULL
AICD	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
even	NULL
if	NULL
both	NULL
JNK	NULL
and	NULL
ERK	NULL
pathways	NULL
are	NULL
operative	NULL
,	NULL
the	NULL
JNK	NULL
pathway	NULL
is	NULL
dominant	NULL
and	NULL
results	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
.	NULL

Conversely	NULL
,	NULL
ERK	NULL
pathway	NULL
may	NULL
represent	NULL
a	NULL
dominant	NULL
pathway	NULL
during	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
survival	NULL
.	NULL

The	NULL
mechanism	NULL
involved	NULL
in	NULL
the	NULL
JNK-pathway	NULL
mediated	NULL
loss	NULL
of	NULL
RXRE-dependent	NULL
transcription	NULL
remains	NULL
unknown	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
study	NULL
(	NULL
46	NULL
)	NULL
,	NULL
hyperphosphorylation	NULL
of	NULL
RXRa	NULL
by	NULL
JNK	NULL
in	NULL
UV	NULL
irradiated	NULL
COS-1	NULL
cells	NULL
did	NULL
not	NULL
effect	NULL
RXRE-dependent	NULL
transcription	NULL
,	NULL
indicating	NULL
that	NULL
direct	NULL
phosphorylation	NULL
of	NULL
RXRa	NULL
may	NULL
not	NULL
contribute	NULL
to	NULL
MEKK1-induced	NULL
down-regulation	NULL
of	NULL
RXRE-dependent	NULL
transcription	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
some	NULL
yet	NULL
unknown	NULL
MEKK1l-activated	NULL
intermediate	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
is	NULL
involved	NULL
in	NULL
this	NULL
inhibition	NULL
.	NULL

This	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
may	NULL
have	NULL
a	NULL
role	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-mediated	NULL
gene	NULL
transcription	NULL
either	NULL
by	NULL
displacing	NULL
some	NULL
important	NULL
cofactor	NULL
or	NULL
through	NULL
some	NULL
other	NULL
mechanism	NULL
and	NULL
needs	NULL
further	NULL
investigation	NULL
.	NULL

Nuclear	NULL
hormone	NULL
receptors	NULL
and	NULL
AP-1	NULL
mutually	NULL
antagonize	NULL
each	NULL
other	NULL
functionally	NULL
,	NULL
either	NULL
by	NULL
recognizing	NULL
common	NULL
regulatory	NULL
se-quences	NULL
,	NULL
a	NULL
phenomenon	NULL
termed	NULL
cross-coupling	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
,	NULL
or	NULL
by	NULL
physically	NULL
interacting	NULL
with	NULL
each	NULL
other	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
other	NULL
mechanisms	NULL
have	NULL
been	NULL
described	NULL
to	NULL
explain	NULL
the	NULL
antagonism	NULL
,	NULL
which	NULL
include	NULL
competition	NULL
for	NULL
limiting	NULL
amounts	NULL
of	NULL
CREB-binding	NULL
protein	NULL
(	NULL
50	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
dependent	NULL
inhibition	NULL
of	NULL
JNK	NULL
pathway	NULL
(	NULL
51	NULL
)	NULL
.	NULL

JNK	NULL
activates	NULL
c-Jun	NULL
by	NULL
phosphorylation	NULL
on	NULL
Ser-63/73	NULL
in	NULL
the	NULL
amino-terminal	NULL
region	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
two	NULL
other	NULL
proteins	NULL
ATF-2	NULL
and	NULL
ELK-1	NULL
,	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
c-Fos	NULL
,	NULL
are	NULL
also	NULL
activated	NULL
by	NULL
JNK	NULL
(	NULL
54	NULL
,	NULL
55	NULL
)	NULL
.	NULL

It	NULL
can	NULL
be	NULL
speculated	NULL
that	NULL
one	NULL
possible	NULL
mechanism	NULL
for	NULL
the	NULL
JNK-mediated	NULL
suppression	NULL
of	NULL
RXRE	NULL
function	NULL
reported	NULL
in	NULL
this	NULL
study	NULL
may	NULL
involve	NULL
antagonism	NULL
of	NULL
RXRE-dependent	NULL
transcription	NULL
by	NULL
JNK-activated	NULL
AP1	NULL
elements	NULL
,	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
MEKK1	NULL
and	NULL
MEK1	NULL
modulate	NULL
the	NULL
transcriptional	NULL
function	NULL
of	NULL
both	NULL
constitutive	NULL
and	NULL
overexpressed	NULL
RXRa	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
MAPK	NULL
pathways	NULL
regulate	NULL
RXRE-driven	NULL
transcription	NULL
independent	NULL
of	NULL
RXRa	NULL
levels	NULL
.	NULL

Because	NULL
CsA	NULL
treatment	NULL
enhances	NULL
the	NULL
RXRa	NULL
accumulation	NULL
but	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
inhibition	NULL
of	NULL
RXRE-driven	NULL
transcription	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
one	NULL
may	NULL
speculate	NULL
that	NULL
CN	NULL
pathways	NULL
regulate	NULL
only	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
levels	NULL
.	NULL

Since	NULL
T	NULL
cell	NULL
activation	NULL
involves	NULL
stimulation	NULL
of	NULL
both	NULL
CN	NULL
and	NULL
MAPK	NULL
pathways	NULL
,	NULL
accumulation	NULL
of	NULL
RXRa	NULL
and	NULL
inhibition	NULL
of	NULL
its	NULL
function	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
stimulation	NULL
of	NULL
both	NULL
of	NULL
these	NULL
pathways	NULL
.	NULL

Thus	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
alone	NULL
may	NULL
not	NULL
be	NULL
a	NULL
measure	NULL
of	NULL
its	NULL
function	NULL
.	NULL

Phosphorylation	NULL
and	NULL
dephosphorylation	NULL
of	NULL
other	NULL
cellular	NULL
factors	NULL
seem	NULL
to	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
defining	NULL
the	NULL
RXRE-dependent	NULL
transcription	NULL
function	NULL
.	NULL

Because	NULL
the	NULL
activation	NULL
of	NULL
cycling	NULL
T	NULL
cells	NULL
eventually	NULL
signals	NULL
the	NULL
growth	NULL
inhibition	NULL
and	NULL
AICD	NULL
,	NULL
loss	NULL
of	NULL
RXRE-dependent	NULL
transcription	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
early	NULL
outcomes	NULL
of	NULL
such	NULL
signaling	NULL
that	NULL
is	NULL
essential	NULL
for	NULL
shutting	NULL
down	NULL
the	NULL
cellular	NULL
machinery	NULL
and	NULL
mediating	NULL
AICD	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

R.	NULL
M.	NULL
Evans	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
P.	NULL
Munoz-Canoves	NULL
,	NULL
K.	NULL
Ozato	NULL
for	NULL
their	NULL
generous	NULL
gift	NULL
of	NULL
plasmid	NULL
constructs	NULL
,	NULL
and	NULL
H.	NULL
T.	NULL
Maecker	NULL
for	NULL
providing	NULL
SupT13	NULL
cells	NULL
.	NULL

We	NULL
thank	NULL
Aruna	NULL
Gaddam	NULL
for	NULL
performing	NULL
ERK	NULL
and	NULL
JNK	NULL
assays	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Marjorie	NULL
Bosche	NULL
and	NULL
Allison	NULL
Hazen	NULL
for	NULL
their	NULL
technical	NULL
help	NULL
and	NULL
Julie	NULL
Metcalf	NULL
for	NULL
providing	NULL
blood	NULL
samples	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Blomhoff	NULL
,	NULL
R.	NULL
1994	NULL
.	NULL

Overview	NULL
of	NULL
vitamin	NULL
A	NULL
metabolism	NULL
and	NULL
function	NULL
.	NULL

In	NULL
Vitamin	NULL
A	NULL
in	NULL
Health	NULL
and	NULL
Disease	NULL
.	NULL

R.	NULL
Blomhoff	NULL
,	NULL
ed	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
,	NULL
p.	NULL
1	NULL
.	NULL

2	NULL
.	NULL

Chambon	NULL
,	NULL
P.	NULL
1994	NULL
.	NULL

The	NULL
retinoid	NULL
signaling	NULL
pathway	NULL
:	NULL
molecular	NULL
and	NULL
genetic	NULL
anal-ysis	NULL
.	NULL

Semin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5	NULL
:	NULL
115	NULL
.	NULL

3	NULL
.	NULL

Chambon	NULL
,	NULL
P.	NULL
1996	NULL
.	NULL

A	NULL
decade	NULL
of	NULL
molecular	NULL
biology	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

10:940	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

REGULATION	NULL
OF	NULL
RXRa	NULL
EXPRESSION	NULL
DURING	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
.	NULL

De	NULL
Luca	NULL
,	NULL
L.	NULL
M.	NULL
1991	NULL
.	NULL

Retinoids	NULL
and	NULL
their	NULL
receptors	NULL
in	NULL
differentiation	NULL
,	NULL
embryo	NULL
genesis	NULL
,	NULL
and	NULL
neoplasia	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2924.	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
retinoid	NULL
receptors	NULL
.	NULL

In	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
and	NULL
Medicine	NULL
.	NULL

M.	NULL
B	NULL
Sporn	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Goodman	NULL
,	NULL
eds	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
,	NULL
p.	NULL
319.	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
RXR	NULL
heterodimers	NULL
and	NULL
orphan	NULL
receptors	NULL
.	NULL

Cell	NULL
83:841.	NULL
.	NULL

Picdrafita	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
Pfahl	NULL
.	NULL

1997	NULL
.	NULL

Retinoid-induced	NULL
apoptosis	NULL
and	NULL
Sp1	NULL
cleav-	NULL
age	NULL
occur	NULL
independently	NULL
of	NULL
transcription	NULL
and	NULL
require	NULL
caspase	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:6348.	NULL
.	NULL

Szondy	NULL
Z.	NULL
,	NULL
U.	NULL
Reichert	NULL
,	NULL
J.-M.	NULL
Bernardon	NULL
,	NULL
S.	NULL
Michel	NULL
,	NULL
T.	NULL
Reka	NULL
,	NULL
and	NULL
E.	NULL
Karaszi	NULL
,	NULL
and	NULL
L.	NULL
Fesus	NULL
.	NULL

1998	NULL
.	NULL

Inhibition	NULL
of	NULL
activation-induced	NULL
apoptosis	NULL
of	NULL
thymocytes	NULL
by	NULL
all-trans-	NULL
and	NULL
9-cis-retinoic	NULL
acid	NULL
is	NULL
mediated	NULL
via	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a.	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

331:767.	NULL
.	NULL

Bissonnette	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
T.	NULL
Brunner	NULL
,	NULL
S.	NULL
B.	NULL
Lazarchik	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
M.	NULL
F.	NULL
Bochm	NULL
,	NULL
D.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Heyman	NULL
.	NULL

1995	NULL
.	NULL

9-cis	NULL
retinoic	NULL
acid	NULL
inhibition	NULL
of	NULL
activation-induced	NULL
apoptosis	NULL
is	NULL
mediated	NULL
via	NULL
regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
and	NULL
requires	NULL
retinoic	NULL
acid	NULL
receptor	NULL
and	NULL
retinoic	NULL
X	NULL
receptor	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:5576	NULL
.	NULL

Iwata	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Mukai	NULL
,	NULL
Y.	NULL
Nakai	NULL
,	NULL
and	NULL
R.	NULL
Iseki.1992	NULL
.	NULL

Retinoic	NULL
acids	NULL
inhibit	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
and	NULL
thymocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149	NULL
;	NULL
3302	NULL
.	NULL

Szondy	NULL
,	NULL
Z.	NULL
,	NULL
U.	NULL
Reichert	NULL
,	NULL
J-M.	NULL
Bernardon	NULL
,	NULL
S.	NULL
Michel	NULL
,	NULL
T.	NULL
Reka	NULL
,	NULL
P.	NULL
Ancian	NULL
,	NULL
E.	NULL
Ajzner	NULL
,	NULL
and	NULL
L.	NULL
Fesus	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
retinoids	NULL
and	NULL
retinoic	NULL
acid	NULL
receptor	NULL
y-selective	NULL
compounds	NULL
in	NULL
mouse	NULL
thymocytes	NULL
through	NULL
a	NULL
novel	NULL
apoptosis	NULL
pathway	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

51:972	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
S.	NULL
Vacchio	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell.1993	NULL
.	NULL

9-Cis-retinoic	NULL
acid	NULL
inhibits	NULL
activation-driven	NULL
T-cell	NULL
apoptosis	NULL
:	NULL
implications	NULL
for	NULL
retinoid	NULL
X	NULL
receptor	NULL
involvement	NULL
in	NULL
thymocyte	NULL
development	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:6170	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Mercep	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
and	NULL
activation-induced	NULL
Fas	NULL
ligand	NULL
mediated	NULL
apoptosis	NULL
of	NULL
T	NULL
cell	NULL
hybridomas	NULL
:	NULL
inhibition	NULL
of	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
glucocorticoids	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1673	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
J.	NULL
Bailey	NULL
,	NULL
M.	NULL
S.	NULL
Vacchio	NULL
,	NULL
R.	NULL
Yarchoan	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1995	NULL
.	NULL

Retinoic	NULL
acid	NULL
inhibition	NULL
of	NULL
ex	NULL
vivo	NULL
human	NULL
immunodeficiency	NULL
virus-associated	NULL
apoptosis	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:3051	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
1996	NULL
.	NULL

T	NULL
cell	NULL
antigen	NULL
receptor	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
,	NULL
14:259	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Jacinto	NULL
,	NULL
M.	NULL
Hibi	NULL
,	NULL
T.	NULL
Kallunki	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
Y.	NULL
Ben-Neriah.1994	NULL
.	NULL

JNK	NULL
is	NULL
involved	NULL
in	NULL
signal	NULL
integration	NULL
during	NULL
costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
77:727	NULL
.	NULL

Dickens	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Rogers	NULL
,	NULL
J.	NULL
Cavanagh	NULL
,	NULL
A.	NULL
Raitano	NULL
,	NULL
Z.	NULL
Xia	NULL
,	NULL
J.	NULL
R.	NULL
Halpern	NULL
,	NULL
M.	NULL
E.	NULL
Greenberg	NULL
,	NULL
C.	NULL
L	NULL
Sawyers	NULL
,	NULL
and	NULL
R.	NULL
J	NULL
Davis	NULL
1997	NULL
.	NULL

A	NULL
cytoplasmic	NULL
inhibitor	NULL
of	NULL
the	NULL
JNK	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

Science	NULL
277:693	NULL
.	NULL

Hoffmeyer	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Gross-Wilde	NULL
,	NULL
E.	NULL
Flory	NULL
,	NULL
B.	NULL
Neufeld	NULL
,	NULL
M.	NULL
Kunz	NULL
,	NULL
U.	NULL
R.	NULL
Rapp	NULL
,	NULL
and	NULL
S.	NULL
Ludwig	NULL
.	NULL

1999	NULL
.	NULL

Different	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
signaling	NULL
pathways	NULL
cooperate	NULL
to	NULL
regulate	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:4319	NULL
.	NULL

Daum	NULL
,	NULL
G.	NULL
,	NULL
I.	NULL
Eisenmann-Tappe	NULL
,	NULL
H.	NULL
W.	NULL
Fries	NULL
,	NULL
J.	NULL
Troppmair	NULL
,	NULL
and	NULL
U.	NULL
R.	NULL
Rapp	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
ins	NULL
and	NULL
outs	NULL
of	NULL
Raf	NULL
kinases	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

11:474	NULL
.	NULL

Yan	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
D.	NULL
Templeton	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
2	NULL
serine	NULL
residues	NULL
of	NULL
MEK-1	NULL
that	NULL
are	NULL
differentially	NULL
phosphorylated	NULL
during	NULL
activation	NULL
by	NULL
raf	NULL
and	NULL
MEK	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:19067	NULL
.	NULL

Zheng	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Guan	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
MEK	NULL
family	NULL
kinases	NULL
requires	NULL
phosphorylation	NULL
of	NULL
two	NULL
conserved	NULL
Ser/Thr	NULL
residues	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:1123	NULL
.	NULL

Lin	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Minden	NULL
,	NULL
H.	NULL
Martinetto	NULL
,	NULL
F.	NULL
X.	NULL
Claret	NULL
,	NULL
C.	NULL
Lange-Carter	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
G.	NULL
L.	NULL
Johnson	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
dual	NULL
specificity	NULL
kinase	NULL
that	NULL
activates	NULL
the	NULL
Jun	NULL
kinases	NULL
and	NULL
p38-Mpk2	NULL
.	NULL

1995	NULL
.	NULL

Science	NULL
268:286	NULL
.	NULL

Xu	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Cobb	NULL
.	NULL

1997	NULL
.	NULL

MEKK1	NULL
binds	NULL
directly	NULL
to	NULL
the	NULL
c-Jun	NULL
N-terminal	NULL
kinases/stress-activated	NULL
protein	NULL
kinases	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:32056	NULL
.	NULL

Minden	NULL
,	NULL
A.	NULL
,	NULL
A	NULL
.	NULL

Lin	NULL
.	NULL

,	NULL
M.	NULL
McMahon	NULL
,	NULL
C.	NULL
Lange-Carter	NULL
,	NULL
B.	NULL
Derijard	NULL
,	NULL
R.	NULL
J.	NULL
Davis	NULL
,	NULL
G.	NULL
L	NULL
Johnson	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
ERK	NULL
and	NULL
JNK	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
by	NULL
Raf-1	NULL
and	NULL
MEKK	NULL
.	NULL

Science	NULL
266:1719	NULL
.	NULL

Wesselborg	NULL
,	NULL
S.	NULL
,	NULL
O.	NULL
Janssen	NULL
,	NULL
and	NULL
D.	NULL
Kabelitz	NULL
.	NULL

1993	NULL
.	NULL

Induction	NULL
of	NULL
activation-driven	NULL
(	NULL
apoptosis	NULL
)	NULL
in	NULL
activated	NULL
but	NULL
not	NULL
resting	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:4338	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
J.	NULL
Mogil	NULL
,	NULL
D.	NULL
Leface	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
A.	NULL
Mahboubi	NULL
,	NULL
F.	NULL
Echeverri	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Martin	NULL
.	NULL

,	NULL
W.	NULL
R.	NULL
Force	NULL
,	NULL
D.	NULL
H.	NULL
Lynch	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1995	NULL
.	NULL

Cell-autonomous	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
/Fas	NULL
ligand	NULL
interaction	NULL
mediates	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

Nature	NULL
373:441	NULL
.	NULL

Dhein	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
C.	NULL
Baumler	NULL
,	NULL
K.-M.	NULL
Debatin	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1995	NULL
.	NULL

Autocrine	NULL
T	NULL
cell-suicide	NULL
mediated	NULL
by	NULL
APO-1/	NULL
(	NULL
Fas/CD95	NULL
)	NULL
.	NULL

Nature	NULL
373:438	NULL
.	NULL

Parijs	NULL
,	NULL
L.	NULL
W.	NULL
,	NULL
A.	NULL
Ibraghimov	NULL
,	NULL
and	NULL
A.	NULL
K.	NULL
Abbas	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
roles	NULL
of	NULL
costimulation	NULL
and	NULL
Fas	NULL
in	NULL
T	NULL
cell	NULL
apoptosis	NULL
and	NULL
peripheral	NULL
tolerance	NULL
.	NULL

Immunity	NULL
4:321	NULL
.	NULL

Ishaq	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
M.	NULL
Zhang	NULL
,	NULL
and	NULL
V.	NULL
Natarajan	NULL
.	NULL

1998	NULL
.	NULL

Activation-induced	NULL
down-regulation	NULL
of	NULL
retinoid	NULL
receptor	NULL
RXRa	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Role	NULL
of	NULL
cell	NULL
cycle	NULL
regulation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:21210	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
S.	NULL
A.	NULL
Kliewer	NULL
,	NULL
U.	NULL
Borgmeyer	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
direct	NULL
repeat	NULL
in	NULL
the	NULL
cellular	NULL
retinol-binding	NULL
protein	NULL
type	NULL
II	NULL
gene	NULL
confers	NULL
differential	NULL
regulation	NULL
by	NULL
RXR	NULL
and	NULL
RAR	NULL
.	NULL

Cell	NULL
66:555	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
K.	NULL
M.	NULL
Higgins	NULL
,	NULL
E.	NULL
Lacy	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
246:1617	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Brabletz	NULL
,	NULL
M.	NULL
Hergenrother	NULL
,	NULL
I.	NULL
Sobotta	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1990	NULL
.	NULL

Cyclosporin	NULL
A	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
binding	NULL
of	NULL
lymphocyte-specific	NULL
factors	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:2529	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

Whitchurst	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
T.	NULL
G.	NULL
Boulton	NULL
,	NULL
M.	NULL
H.	NULL
Cobb	NULL
,	NULL
and	NULL
T.	NULL
D.	NULL
Geppart	NULL
.	NULL

1992	NULL
.	NULL

Extracellular	NULL
signal-regulated	NULL
kinases	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Anti-CD3	NULL
and	NULL
46-phorbol	NULL
12-myris-tate	NULL
13-acetate-induced	NULL
phosphorylation	NULL
and	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:3230	NULL
.	NULL

Zhang	NULL
,	NULL
J.	NULL
,	NULL
K.V	NULL
.	NULL

Salojin	NULL
,	NULL
J-X	NULL
.	NULL

Gao	NULL
,	NULL
M.	NULL
J.	NULL
Cameron	NULL
,	NULL
I.	NULL
Bergerot	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Delovich	NULL
.	NULL

1999.	NULL
p38	NULL
Mitogen-activated	NULL
protein	NULL
kinase	NULL
mediates	NULL
signal	NULL
integration	NULL
of	NULL
TCR/	NULL
CD28	NULL
costimulation	NULL
in	NULL
primary	NULL
murine	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:3819	NULL
.	NULL

Hahn	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
S.	NULL
S.	NULL
Yoon	NULL
,	NULL
H.	NULL
W.	NULL
Sohn	NULL
,	NULL
H.	NULL
G.	NULL
Song	NULL
,	NULL
S.	NULL
H.	NULL
Park	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Kim	NULL
.	NULL

2000	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
MAP	NULL
kinase	NULL
family	NULL
members	NULL
triggered	NULL
by	NULL
CD99	NULL
engagement	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

470:350	NULL
.	NULL

Yu	NULL
,	NULL
V.	NULL
C.	NULL
,	NULL
C.	NULL
Delsert	NULL
,	NULL
B.	NULL
Anderson	NULL
,	NULL
J.	NULL
M.	NULL
Holloway	NULL
,	NULL
O.	NULL
Devary	NULL
,	NULL
A.	NULL
M.	NULL
Naar	NULL
,	NULL
S.	NULL
Y.	NULL
Kim	NULL
,	NULL
J.	NULL
M.	NULL
Boutin	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1991	NULL
.	NULL

RXRB	NULL
:	NULL
a	NULL
coregulator	NULL
that	NULL
enhances	NULL
binding	NULL
of	NULL
retinoic	NULL
acid	NULL
,	NULL
thyroid	NULL
hormone	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
receptors	NULL
to	NULL
their	NULL
cognate	NULL
response	NULL
elements	NULL
.	NULL

Cell	NULL
67:1251	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
K.	NULL
,	NULL
B.	NULL
Hoffmann	NULL
,	NULL
P.	NULL
B.	NULL
V.	NULL
Tran	NULL
,	NULL
G.	NULL
Graupner	NULL
,	NULL
and	NULL
M.	NULL
Phahl	NULL
.	NULL

1992	NULL
.	NULL

Retinoid	NULL
X	NULL
receptor	NULL
is	NULL
an	NULL
auxiliary	NULL
protein	NULL
for	NULL
thyroid	NULL
hormone	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Nature	NULL
355:441	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
D.	NULL
J.	NULL
Noonan	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1992	NULL
.	NULL

Convergence	NULL
of	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
and	NULL
peroxisome	NULL
proliferator	NULL
signaling	NULL
pathways	NULL
through	NULL
heterodimer	NULL
formation	NULL
of	NULL
their	NULL
receptors	NULL
.	NULL

Nature	NULL
358:771	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
K.	NULL
Umesona	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1992	NULL
.	NULL

Retinoid	NULL
X	NULL
receptor-COUP-TF	NULL
interactions	NULL
modulate	NULL
retinoic	NULL
acid	NULL
signaling	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1448	NULL
.	NULL

Flanagan	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
B.	NULL
Corthesy	NULL
,	NULL
R.	NULL
J.	NULL
Bram	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
association	NULL
of	NULL
a	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
blocked	NULL
by	NULL
FK-506	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Nature	NULL
352:803	NULL
.	NULL

Isakov	NULL
,	NULL
N.	NULL
1998	NULL
.	NULL

Regulation	NULL
of	NULL
T-cell-derived	NULL
protein	NULL
kinase	NULL
C	NULL
activity	NULL
by	NULL
vitamin	NULL
A	NULL
derivatives	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

115:288	NULL
.	NULL

Felli	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
A.	NULL
Vacca	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
via	NULL
cis-regulatory	NULL
sequences	NULL
containing	NULL
an	NULL
octamer	NULL
motif	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:4771	NULL
.	NULL

Li	NULL
,	NULL
W.	NULL
,	NULL
C.	NULL
D.	NULL
Whaley	NULL
,	NULL
A.	NULL
Mondino	NULL
,	NULL
D.	NULL
L.	NULL
Mueller	NULL
.	NULL

1996	NULL
.	NULL

Blocked	NULL
signal	NULL
transduction	NULL
to	NULL
the	NULL
ERK	NULL
and	NULL
JNK	NULL
protein	NULL
kinases	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
271:1272	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

4225	NULL
.	NULL

Xia	NULL
,	NULL
Z.	NULL
,	NULL
M.	NULL
Dickens	NULL
,	NULL
J.	NULL
Raingeaud	NULL
,	NULL
R.	NULL
J.	NULL
Davis	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1995	NULL
.	NULL

Opposing	NULL
effects	NULL
of	NULL
ERK	NULL
and	NULL
JNK-p38	NULL
MAP	NULL
kinases	NULL
on	NULL
apoptosis	NULL
.	NULL

Science	NULL
270	NULL
:	NULL
1326	NULL
.	NULL

Sugawara	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Moriguchi	NULL
,	NULL
E.	NULL
Nishida	NULL
,	NULL
and	NULL
Y.	NULL
Takahama	NULL
.	NULL

1998	NULL
.	NULL

Differential	NULL
roles	NULL
of	NULL
ERK	NULL
and	NULL
p38	NULL
MAP	NULL
kinase	NULL
pathways	NULL
in	NULL
positive	NULL
and	NULL
negative	NULL
selection	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Immunity	NULL
9:565	NULL
.	NULL

Adam-Stitah	NULL
,	NULL
S.	NULL
,	NULL
L.	NULL
Penna	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
C.	NULL
Rochette-Egly	NULL
.	NULL

1999	NULL
.	NULL

Hyperphosphorylation	NULL
of	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
a	NULL
by	NULL
activated	NULL
c-Jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinases	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:18932	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Cross-coupling	NULL
of	NULL
signal	NULL
transduction	NULL
path-ways	NULL
:	NULL
zinc	NULL
finger	NULL
meets	NULL
leucine	NULL
zipper	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

7:377	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rangarajan	NULL
,	NULL
S.	NULL
Kliewer	NULL
,	NULL
L.	NULL
J	NULL
Ransone	NULL
,	NULL
J.	NULL
Bolado	NULL
,	NULL
N.	NULL
Yang	NULL
,	NULL
I.	NULL
M.	NULL
Verma	NULL
,	NULL
and	NULL
R.	NULL
M	NULL
Evans.1990	NULL
.	NULL

Functional	NULL
antagonism	NULL
between	NULL
oncoprotein	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
62:1217	NULL
.	NULL

Pfahl	NULL
,	NULL
M.	NULL
1993	NULL
.	NULL

Nuclear	NULL
receptor/AP-1	NULL
interaction	NULL
.	NULL

Endocr	NULL
.	NULL

Rev	NULL
.	NULL

5:651	NULL
.	NULL

Kamei	NULL
,	NULL
Y.	NULL
,	NULL
L.	NULL
Xu	NULL
,	NULL
T.	NULL
Heinzel	NULL
,	NULL
J.	NULL
Torchia	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
B	NULL
.	NULL

Gloss	NULL
,	NULL
S.	NULL
C.	NULL
Lin	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
D.	NULL
W.	NULL
Rose	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
CBP	NULL
integrator	NULL
complex	NULL
mediates	NULL
transcriptional	NULL
activation	NULL
and	NULL
AP-1	NULL
inhibition	NULL
by	NULL
nuclear	NULL
receptors	NULL
.	NULL

Cell	NULL
85:403	NULL
.	NULL

Caelles	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
M.	NULL
Gonzalez-Sancho	NULL
,	NULL
and	NULL
A.	NULL
Munoz	NULL
.	NULL

1997	NULL
Nuclear	NULL
hormone	NULL
receptor	NULL
antagonism	NULL
with	NULL
AP-1	NULL
by	NULL
inhibition	NULL
of	NULL
the	NULL
JNK	NULL
pathway	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:3351	NULL
.	NULL

Pulverer	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
J.	NULL
M.	NULL
Kyriakis	NULL
,	NULL
J.	NULL
Avruch	NULL
,	NULL
E.	NULL
Nikolakaki	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Woodgett	NULL
.	NULL

1991	NULL
.	NULL

Phosphorylation	NULL
of	NULL
c-jun	NULL
mediated	NULL
by	NULL
MAP	NULL
kinases	NULL
.	NULL

Nature	NULL
353:670	NULL
.	NULL

Smeal	NULL
,	NULL
T.	NULL
,	NULL
B.	NULL
Binetruy	NULL
,	NULL
D.A	NULL
.	NULL

Mercola	NULL
,	NULL
M.	NULL
Birrer	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1991	NULL
.	NULL

Oncogenic	NULL
and	NULL
transcriptional	NULL
cooperation	NULL
with	NULL
Ha-Ras	NULL
requires	NULL
phosphorylation	NULL
of	NULL
c-Jun	NULL
on	NULL
serines	NULL
63	NULL
and	NULL
73	NULL
.	NULL

Nature	NULL
354:494	NULL
.	NULL

Gupta	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
B.	NULL
Derijard	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Davis	NULL
.	NULL

1995	NULL
.	NULL

Transcription	NULL
factor	NULL
ATF2	NULL
regulation	NULL
by	NULL
the	NULL
JNK	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

Science	NULL
267:389	NULL
.	NULL

Cavigelli	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
Dolfi	NULL
,	NULL
F.	NULL
X.	NULL
Claret	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
c-	NULL
fos	NULL
expression	NULL
through	NULL
JNK-mediated	NULL
TCP/Elk-1	NULL
phosphorylation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:5957	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

